


<OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
         xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
    <responseDate>2025-09-09T13:52:41Z</responseDate>
    <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:12406254" metadataPrefix="pmc">https://pmc.ncbi.nlm.nih.gov/api/oai/v1/mh/</request>
    
    <GetRecord>
        <record>
    <header>
    <identifier>oai:pubmedcentral.nih.gov:12406254</identifier>
    <datestamp>2025-09-04</datestamp>
    
        
        <setSpec>pmc-open</setSpec>
        
    
</header>
    <metadata>
        
        <article xmlns="https://jats.nlm.nih.gov/ns/archiving/1.4/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.4/ https://jats.nlm.nih.gov/archiving/1.4/xsd/JATS-archivearticle1-4.xsd" xml:lang="en" id="c800369964" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Mol Pharm</journal-id><journal-id journal-id-type="iso-abbrev">Mol Pharm</journal-id><journal-id journal-id-type="pmc-domain-id">822</journal-id><journal-id journal-id-type="pmc-domain">acssd</journal-id><journal-id journal-id-type="publisher-id">mp</journal-id><journal-title-group><journal-title>Molecular Pharmaceutics</journal-title></journal-title-group><issn pub-type="ppub">1543-8384</issn><issn pub-type="epub">1543-8392</issn><self-uri>pubs.acs.org/molecularpharmaceutics</self-uri><custom-meta-group><custom-meta><meta-name>pmc-is-collection-domain</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-collection-title</meta-name><meta-value>ACS AuthorChoice</meta-value></custom-meta></custom-meta-group></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12406254</article-id><article-id pub-id-type="pmcid-ver">PMC12406254.1</article-id><article-id pub-id-type="pmcaid">12406254</article-id><article-id pub-id-type="pmcaiid">12406254</article-id><article-id pub-id-type="pmid">40763217</article-id><article-id pub-id-type="doi">10.1021/acs.molpharmaceut.5c00742</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>MMP-Sensitive
Macrophage-Targeted Coenzyme Q10 Nanomedicine
for Rheumatoid Arthritis Treatment</article-title></title-group><contrib-group id="CONTRIB-GROUP-d14e23-autogenerated"><contrib id="ath1" contrib-type="author"><contrib-id contrib-id-type="paragon-plus" authenticated="true">7507939</contrib-id><name name-style="western"><surname>Akram</surname><given-names initials="A">Aasma</given-names></name><xref rid="aff1" ref-type="aff"/><xref rid="aff2" ref-type="aff"/></contrib><contrib id="ath2" contrib-type="author"><contrib-id contrib-id-type="paragon-plus" authenticated="true">7506242</contrib-id><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0009-0009-1885-2993</contrib-id><name name-style="western"><surname>Ara</surname><given-names initials="N">Nishat</given-names></name><xref rid="aff1" ref-type="aff"/></contrib><contrib id="ath3" contrib-type="author"><contrib-id contrib-id-type="paragon-plus" authenticated="true">7507926</contrib-id><name name-style="western"><surname>Bhattarai</surname><given-names initials="P">Prapanna</given-names></name><xref rid="aff1" ref-type="aff"/></contrib><contrib id="ath4" contrib-type="author" corresp="yes"><contrib-id contrib-id-type="paragon-plus" authenticated="true">7045243</contrib-id><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0009-0006-5282-4791</contrib-id><name name-style="western"><surname>Irfan</surname><given-names initials="M">Muhammad</given-names></name><xref rid="cor2" ref-type="corresp"/><xref rid="aff2" ref-type="aff"/></contrib><contrib id="ath5" contrib-type="author" corresp="yes"><contrib-id contrib-id-type="paragon-plus" authenticated="true">2144039</contrib-id><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-4047-1726</contrib-id><name name-style="western"><surname>Zhu</surname><given-names initials="L">Lin</given-names></name><xref rid="cor1" ref-type="corresp"/><xref rid="aff1" ref-type="aff"/></contrib><aff id="aff1">
<label>&#8224;</label>
<institution content-type="dept">Department
of Pharmaceutical Sciences, Irma Lerma Rangel College of Pharmacy</institution>, <institution-wrap><institution-id institution-id-type="Ringgold" specific-use="source:pplus">14736</institution-id><institution>Texas A&amp;M University</institution></institution-wrap>, <city>College Station</city>, <state>Texas</state>
<postal-code>77843</postal-code>, <country>United States</country>
</aff><aff id="aff2">
<label>&#8225;</label>
<institution content-type="dept">Department
of Pharmaceutics, Faculty of Pharmaceutical Sciences</institution>, <institution-wrap><institution-id institution-id-type="Ringgold" specific-use="source:pplus">72594</institution-id><institution>Government College University Faisalabad</institution></institution-wrap>, <city>Faisalabad</city>
<postal-code>38000</postal-code>, <country>Pakistan</country>
</aff></contrib-group><author-notes><corresp id="cor1"><label>*</label>E-mail: <email>lzhu@tamu.edu</email>.</corresp><corresp id="cor2"><label>*</label>E-mail: <email>drmirfan@gcuf.edu.pk</email>.</corresp></author-notes><pub-date date-type="pub" publication-format="electronic"><day>05</day><month>8</month><year>2025</year></pub-date><pub-date date-type="collection" publication-format="electronic"><day>01</day><month>9</month><year>2025</year></pub-date><volume>22</volume><issue>9</issue><issue-id pub-id-type="pmc-issue-id">496131</issue-id><fpage>5638</fpage><lpage>5651</lpage><history><date date-type="received"><day>22</day><month>5</month><year>2025</year></date><date date-type="accepted"><day>29</day><month>7</month><year>2025</year></date><date date-type="rev-recd"><day>28</day><month>7</month><year>2025</year></date><date date-type="online"><day>05</day><month>8</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>03</day><month>09</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>04</day><month>09</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-09-04 10:25:45.023"><day>04</day><month>09</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; 2025 The Authors. Published by American Chemical Society</copyright-statement><copyright-year>2025</copyright-year><copyright-holder>The Authors</copyright-holder><ali:free_to_read content-type="AuthorChoicev2" start_date="2025-08-05"/><license><ali:license_ref specific-use="textmining" content-type="ccbylicense" start_date="2025-08-05">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is licensed under CC-BY 4.0</license-p></license></permissions><self-uri content-type="pmc-pdf" xlink:href="mp5c00742.pdf"/><abstract><p>In this work, a novel nanoparticle (NP)-based formulation
(i.e.,
nanomedicine) was developed to specifically deliver coenzyme Q10 (CoQ10)
to macrophages for treating rheumatoid arthritis (RA). The NPs containing
the matrix metalloproteinase (MMP)-responsive polymer, polyethylene
glycol&#8211;peptide&#8211;phosphatidylethanolamine (PEG-pp-PE),
and phosphatidylserine were designed, in which the NPs&#8217; PEG
&#8220;corona&#8221; decreased nonspecific interaction, and the
overexpressed MMP-2/9 in the inflamed synovium triggered PEG deshielding
and PS-mediated phagocytosis. The NPs were prepared by a thin-film
hydration method, and their particle size, zeta potential, drug loading,
and drug release were determined. CoQ10 could be loaded into the NPs
with a drug loading of about 9.7% at the polymer/PS ratio of 50:50.
The CoQ10-loaded NPs had a particle size of &lt;200 nm and a zeta
potential of &#8764;&#8722;40 mV and showed sustained drug release
under simulated sink conditions at 37 &#176;C. In the presence of
MMPs, the NPs were efficiently taken up by macrophages (RAW264.7 cells)
with cellular uptake 3.5-fold higher than that of the NPs in the absence
of MMPs. More significantly, the NPs&#8217; uptake in RAW264.7 cells
was &gt;13-fold higher than that in fibroblasts (NIH3T3 cells) in
the
presence of MMPs, whereas this difference was &#8764;2-fold in the
absence of MMPs, indicating the NPs&#8217; MMP-sensitive macrophage
selectivity. In the LPS- and IFN-&#947;-stimulated macrophages or
cell cocultures, the CoQ10-loaded NPs significantly inhibited the
production of pro-inflammatory cytokines (TNF-&#945;, IL-6, and IL-1&#946;),
while enhancing the production of the anti-inflammatory cytokine (IL-10)
in response to MMP pretreatment. The CoQ10-loaded NPs also significantly
inhibited macrophage activation, as evidenced by changes in cell morphology
and alterations in macrophage activation-related markers, including
CD80, CD86, MHCII, and CD206. The CoQ10-loaded NPs did not show significant
cytotoxicity in the tested cells. Our results suggest that the developed
MMP-sensitive macrophage-targeted NPs might work as a &#8220;smart&#8221;
nanomedicine for RA treatments.</p></abstract><abstract abstract-type="graphical"><graphic id="agr1" position="float" orientation="portrait" xlink:href="mp5c00742_0018.jpg"/></abstract><abstract abstract-type="toc-graphic"><graphic id="tgr1" position="float" orientation="portrait" xlink:href="mp5c00742_0016.jpg"/></abstract><kwd-group><kwd>nanomedicine</kwd><kwd>nanoparticles</kwd><kwd>macrophage targeting</kwd><kwd>rheumatoid arthritis, coenzyme Q10</kwd><kwd>inflammation</kwd></kwd-group><funding-group><award-group id="fnd-1"><funding-source><institution-wrap><institution>Congressionally Directed Medical Research Programs</institution><institution-id institution-id-type="doi" vocab="open-funder-registry" vocab-identifier="10.13039/open_funder_registry">10.13039/100000090</institution-id></institution-wrap></funding-source><award-id>HT9425-23-1-0119</award-id></award-group></funding-group><funding-group><award-group id="fnd-2"><funding-source><institution-wrap><institution>Texas A and M University</institution><institution-id institution-id-type="doi" vocab="open-funder-registry" vocab-identifier="10.13039/open_funder_registry">10.13039/100007904</institution-id></institution-wrap></funding-source><award-id>NA</award-id></award-group></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>document-id-old-9</meta-name><meta-value>mp5c00742</meta-value></custom-meta><custom-meta><meta-name>document-id-new-14</meta-name><meta-value>mp5c00742</meta-value></custom-meta><custom-meta><meta-name>production-flag-MathML-config-version</meta-name><meta-value>3</meta-value></custom-meta><custom-meta><meta-name>production-flag-journal-citation-display-style</meta-name><meta-value>acs-titles</meta-value></custom-meta><custom-meta><meta-name>production-flag-journal-date-display-style</meta-name><meta-value>dates-used-rcd-rvd-acc</meta-value></custom-meta><custom-meta><meta-name>production-flag-si-avail</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>document-id-alt-64</meta-name><meta-value>cb291564afd3a264f64b564868b8f0601211e1ba04f269a63b4c0429f94fcb23</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="sec1"><label>1</label><title>Introduction</title><p>Rheumatoid arthritis (RA)
is an autoimmune disorder that affects
around 1% of the population. Though major research has been carried
out to study RA, its etiology remains vague.<xref rid="ref1" ref-type="bibr"/> Pathophysiological studies have linked RA to inflammation, cartilage
degradation, and bone erosion, during which macrophages are activated
and have an appreciable role in RA progression.<named-content content-type="bibref-group">
<xref rid="ref2" ref-type="bibr"/>,<xref rid="ref3" ref-type="bibr"/>
</named-content> During
RA, a large number of macrophages are recruited to the inflamed synovium
and become activated to produce inflammatory mediators such as tumor
necrosis factor-alpha (TNF-&#945;), interleukin-6 (IL-6), interleukin-1
beta (IL-1&#946;), prostaglandins, and reactive oxygen species (ROS),
responsible for inflammation and bone damage.<named-content content-type="bibref-group">
<xref rid="ref4" ref-type="bibr"/>&#8722;<xref rid="ref5" ref-type="bibr" specific-use="suppress-in-print"/>
<xref rid="ref6" ref-type="bibr"/>
</named-content> It is also an
established fact that the presence of macrophages in the inflamed
joint leads to an increased number of osteoclasts, resulting in bone
resorption.<named-content content-type="bibref-group">
<xref rid="ref7" ref-type="bibr"/>,<xref rid="ref8" ref-type="bibr"/>
</named-content> Therefore, macrophages are considered to
be an important therapeutic target for RA therapy.</p><p>The nonsteroidal
anti-inflammatory drugs (NSAIDs), e.g., flurbiprofen,
diclofenac, lornoxicam, diflunisal, etc., and disease-modifying antirheumatic
drugs (DMARDs), e.g., hydroxychloroquine, azathioprine, methotrexate,
etc., are currently used for RA treatment.<named-content content-type="bibref-group">
<xref rid="ref9" ref-type="bibr"/>,<xref rid="ref10" ref-type="bibr"/>
</named-content> However,
serious adverse effects have been observed in patients with the long-term
use of these drugs. Biologics, such as anti-TNF-&#945; and anti-IL-6
antibodies, are also used to treat RA. Unfortunately, around 40% of
RA patients do not respond to such antibody therapies<named-content content-type="bibref-group">
<xref rid="ref11" ref-type="bibr"/>,<xref rid="ref12" ref-type="bibr"/>
</named-content> and the treated patients may also be at higher risk of infections.<named-content content-type="bibref-group">
<xref rid="ref10" ref-type="bibr"/>,<xref rid="ref13" ref-type="bibr"/>
</named-content> Besides, these drugs are given systemically through the oral route
or injection, which may cause nonspecific drug biodistribution and
consequent toxicity or damage to healthy tissues and organs. Therefore,
it is critical to develop safe and efficient medicines for RA treatment.
A straightforward strategy is to use targeted drug delivery to improve
the specificity of anti-RA drugs to macrophages in the inflamed tissues.<xref rid="ref12" ref-type="bibr"/>
</p><p>Phosphatidylserine,<xref rid="ref14" ref-type="bibr"/> an anionic cellular
lipid, is found in the inner leaflet of the cell membrane, and its
cellular location is maintained by amino phospholipid translocase
in healthy cells. PS is genetically translocated from the plasma membrane&#8217;s
inner side to its outer layer during cell apoptosis, and the PS externalization
acts as an &#8220;eat me&#8221; signal to trigger phagocytosis.<named-content content-type="bibref-group">
<xref rid="ref15" ref-type="bibr"/>,<xref rid="ref16" ref-type="bibr"/>
</named-content> In addition to working as an immune modulator to suppress inflammation,<named-content content-type="bibref-group">
<xref rid="ref17" ref-type="bibr"/>&#8722;<xref rid="ref18" ref-type="bibr" specific-use="suppress-in-print"/>
<xref rid="ref19" ref-type="bibr" specific-use="suppress-in-print"/>
<xref rid="ref20" ref-type="bibr" specific-use="suppress-in-print"/>
<xref rid="ref21" ref-type="bibr"/>
</named-content> PS has been used as a ligand in drug delivery systems to deliver
drugs to areas with an abundance of phagocytic cells.<named-content content-type="bibref-group">
<xref rid="ref22" ref-type="bibr"/>&#8722;<xref rid="ref23" ref-type="bibr" specific-use="suppress-in-print"/>
<xref rid="ref24" ref-type="bibr" specific-use="suppress-in-print"/>
<xref rid="ref25" ref-type="bibr"/>
</named-content> However, PS is a &#8220;pan-specific&#8221; ligand and cannot
differentiate between macrophages in disease sites and macrophages
in healthy tissues. The disease specificity of PS-containing systems
needs to be improved.</p><p>Matrix metalloproteinases (MMPs) are major
extracellular enzymes
that are zinc-dependent endopeptidases. MMPs are upregulated in inflammation-related
diseases, such as cancer<xref rid="ref26" ref-type="bibr"/> and RA.<xref rid="ref27" ref-type="bibr"/> MMP2 and MMP9 have been found to be overexpressed
in the joints of RA patients, contributing to inflammation and joint
destruction.<named-content content-type="bibref-group">
<xref rid="ref28" ref-type="bibr"/>&#8722;<xref rid="ref29" ref-type="bibr" specific-use="suppress-in-print"/>
<xref rid="ref30" ref-type="bibr" specific-use="suppress-in-print"/>
<xref rid="ref31" ref-type="bibr"/>
</named-content> MMPs have been therapeutic targets for the development of MMP inhibitors.
However, MMP inhibitors can be a double-edged sword in treating RA
due to MMPs&#8217; important roles of MMPs in both physiology and
pathology.<xref rid="ref32" ref-type="bibr"/> Alternatively, MMPs can work
as local stimuli for on-demand &#8220;smart&#8221; drug delivery.<xref rid="ref26" ref-type="bibr"/> So far, several MMP2/9-responsive delivery systems,
such as liposomes<named-content content-type="bibref-group">
<xref rid="ref33" ref-type="bibr"/>,<xref rid="ref34" ref-type="bibr"/>
</named-content> and micelles,<named-content content-type="bibref-group">
<xref rid="ref35" ref-type="bibr"/>,<xref rid="ref36" ref-type="bibr"/>
</named-content> have been developed for targeted drug delivery to treat a variety
of diseases, including cancer and inflammatory diseases such as RA.<named-content content-type="bibref-group">
<xref rid="ref27" ref-type="bibr"/>,<xref rid="ref37" ref-type="bibr"/>,<xref rid="ref38" ref-type="bibr"/>
</named-content> In our previous studies, the
MMP-sensitive self-assembling copolymer PEG-pp-PE, which consists
of an MMP-cleavable peptide (PP), polyethylene glycol (PEG), and phosphoethanolamine
(PE), was synthesized for the preparation of MMP-responsive nanocarriers.<named-content content-type="bibref-group">
<xref rid="ref33" ref-type="bibr"/>,<xref rid="ref34" ref-type="bibr"/>,<xref rid="ref39" ref-type="bibr"/>,<xref rid="ref40" ref-type="bibr"/>
</named-content>
</p><p>Coenzyme Q10 (CoQ10) is an important hydrophobic endogenous
antioxidant
present in cell membranes.<named-content content-type="bibref-group">
<xref rid="ref41" ref-type="bibr"/>,<xref rid="ref42" ref-type="bibr"/>
</named-content> CoQ10 has also been
reported to inhibit pro-inflammatory factors, including nuclear factor-kappa
B (NF-&#954;B), and promote anti-inflammatory factors, such as microRNA-146a
(miR-146a) and nuclear factor erythroid 2-related factor 2 (Nrf2),
resulting in the suppression of inflammation.<named-content content-type="bibref-group">
<xref rid="ref43" ref-type="bibr"/>,<xref rid="ref44" ref-type="bibr"/>
</named-content> Due to its poor aqueous solubility and low bioavailability, high
doses of CoQ10 are usually needed, making drug formulation and administration
difficult.</p><p>In this work, our goal was to develop an MMP2/9-sensitive
drug
delivery system for targeted delivery of CoQ10 to the activated macrophages
in the inflamed synovium, to improve CoQ10&#8217;s anti-inflammatory
effects and reduce its off-target adverse effects. We prepared the
MMP-responsive PS-containing polymeric nanoparticles (NPs), a dual-targeting
system, which could respond to the overexpressed MMPs in the inflammatory
tissues to ensure site-specific drug delivery and mimic PS externalization
for macrophage-specific drug uptake in the inflamed tissues (see the
delivery strategy in <xref rid="fig1" ref-type="fig">Figure <xref rid="fig1" ref-type="fig"/>
</xref>).</p><fig position="float" id="fig1" fig-type="figure" orientation="portrait"><label>1</label><caption><p>Schematic illustration of the CoQ10-loaded MMP-sensitive macrophage-targeted
nanomedicine for RA treatment. In normal tissues with low levels of
MMP2/9, the NPs&#8217; polyethylene glycol (PEG) shields the PS and
prevents nonspecific phagocytosis (to mimic &#8220;don&#8217;t eat
me&#8221; signal). In the presence of overexpressed MMP2/9 in RA,
the MMP-sensitive peptide linker (pp) is cleaved, leading to PEG deshielding
and PS exposure on the surface of the NPs, which acts as an &#8220;eat
me&#8221; signal for PS-mediated phagocytosis.</p></caption><graphic id="gr1" position="float" orientation="portrait" xlink:href="mp5c00742_0001.jpg"/></fig></sec><sec id="sec2"><label>2</label><title>Materials and Methods</title><sec id="sec2.1"><label>2.1</label><title>Materials and Cell Culture</title><p>The MMP-sensitive
peptide (GPLGIAGQ) was synthesized by GenScript USA Inc. (Piscataway,
NJ, USA). Methoxy polyethylene glycol (2,000 Da)-succinimidyl valerate
(PEG2k-SVA) and 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[amino&#173;(polyethylene
glycol)-2000] (PEG2k-PE) were obtained from Laysan Bio, Inc. (Arab,
AL, USA). 1,2-dipalmitoyl-sn-glycero-3-phospho-L-serine (sodium salt,
DPPS), 1,2-dioleoyl-sn-glycero-3 phosphoethanolamine (DOPE), 1,2-dipalmitoyl-sn-glycero-3-phosphocholine
(DPPC), and 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine-N-(lissamine
rhodamine B sulfonyl) (Rh-PE) were purchased from Avanti Polar Lipids,
Inc. (Alabaster, AL, USA). Collagenase (Type IV), N-hydroxysuccinimide
(NHS), and 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride
(EDC) were purchased from Sigma-Aldrich (St. Louis, MO, USA). Triethylamine
(TEA) and dimethylformamide (DMF) were obtained from Thermo Fisher
Scientific (Rockford, IL, USA). The glass-backed TLC plates coated
with silica gel 60 F254 were purchased from EMD Biosciences (La Jolla,
CA, USA). CoQ10 was purchased from Chem-Impex International (Wood
Dale, IL, USA). Dulbecco&#8217;s Modified Eagle&#8217;s Medium (DMEM),
heat-inactivated fetal bovine serum (FBS), and Penicillin-Streptomycin
were purchased from Corning Life Sciences (Tewksbury, MA, USA). All
other ingredients were of analytical grade.</p><p>Mouse macrophages
(RAW 264.7) and fibroblasts (NIH 3T3) were obtained from the American
Type Culture Collection (ATCC) (Manassas, VA, USA). Both cell types
were maintained in complete growth media (DMEM supplemented with 10%
FBS and 1% Penicillin-Streptomycin) at 37 &#176;C in a humidified
atmosphere with 5% CO<sub>2</sub>.</p></sec><sec id="sec2.2"><label>2.2</label><title>Polymer Synthesis and Nanoparticle Preparation</title><p>PEG-pp-PE was synthesized in accordance with our previously reported
method.<named-content content-type="bibref-group">
<xref rid="ref33" ref-type="bibr"/>,<xref rid="ref39" ref-type="bibr"/>
</named-content> The polymeric NPs were prepared via self-assembly
by using the thin-film hydration method. In this study, three types
of NPs were prepared, including <bold>STNPs</bold> (<italic toggle="yes">PEG-pp-PE/PS</italic>), the MMP-<underline>
<bold>S</bold>
</underline>ensitive macrophage <underline>
<bold>T</bold>
</underline>argeting <underline>
<bold>NPs</bold>
</underline>; <bold>SNNPs</bold> (<italic toggle="yes">PEG-pp-PE/PC</italic>), the MMP-<underline>
<bold>S</bold>
</underline>ensitive macrophage <underline>
<bold>N</bold>
</underline>ontargeting <underline>
<bold>NPs</bold>
</underline>;
and <bold>NTNPs</bold> (<italic toggle="yes">PEG-PE/PS</italic>), the <underline>
<bold>N</bold>
</underline>onsensitive macrophage <underline>
<bold>T</bold>
</underline>argeting <underline>
<bold>NPs</bold>
</underline>. For STNPs, three formulations with different PEG-pp-PE/PS ratios
(75/25, 50/50, or 25/75 wt %) were prepared for formulation optimization.</p><p>Here, STNPs were used as an example to explain the preparation
procedure. Briefly, PEG-pp-PE and DPPS were dissolved in a methanol
and chloroform mixture and dried to form a thin lipid-polymer film
by solvent evaporation. Then, the thin film was hydrated with PBS
by vortexing and mild probe sonication. To prepare fluorescent dye-
or drug-loaded NPs, Rh-PE (0.5 wt %) or CoQ10 dissolved in methanol
was added to the PEG-pp-PE and DPPS mixture, followed by the thin-film
hydration method.</p></sec><sec id="sec2.3"><label>2.3</label><title>Drug Loading and Encapsulation Efficiency</title><p>The drug loading and encapsulation of STNPs were measured. A 1
&#956;g portion of the STNP formulation (PEG-pp-PE and PS) and 0.1
mg of CoQ10 were dissolved in an organic solvent and dried to form
a drug-containing thin film, followed by probe sonication. The STNPs
were centrifuged at 14,000 rpm for 15 min to remove unencapsulated
drugs. The supernatant with the drug-loaded NPs was collected. To
measure the CoQ10 content, methanol was added to the NPs to extract
encapsulated drugs, followed by UV absorbance measurement at the &#955;<sub>max</sub> of 275 nm with a microplate reader (Tecan). The following
formulas were used to determine the drug loading and encapsulation
efficiency.<disp-formula id="ueq1"><alternatives><graphic position="float" orientation="portrait" xlink:href="mp5c00742_m001.jpg"/><mml:math id="d1e417" display="block"><mml:mrow><mml:mi>Drug loading</mml:mi><mml:mrow><mml:mspace width=".25em"/><mml:mo stretchy="false">(</mml:mo><mml:mo>%</mml:mo><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mi mathvariant="normal">Weight of encapsulated drugs</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">Weight of drug&#8208;loaded nanoparticles</mml:mi></mml:mrow></mml:mfrac><mml:mo>&#215;</mml:mo><mml:mn>100</mml:mn><mml:mo>%</mml:mo></mml:mrow></mml:math></alternatives></disp-formula>
<disp-formula id="ueq2"><alternatives><graphic position="float" orientation="portrait" xlink:href="mp5c00742_m002.jpg"/><mml:math id="d1e441" display="block"><mml:mrow><mml:mi>Encapsulation efficiency</mml:mi><mml:mrow><mml:mspace width=".25em"/><mml:mo stretchy="false">(</mml:mo><mml:mo>%</mml:mo><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mi mathvariant="normal">Weight of encapsulated drugs</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">Total drugs</mml:mi></mml:mrow></mml:mfrac><mml:mo>&#215;</mml:mo><mml:mn>100</mml:mn><mml:mo>%</mml:mo></mml:mrow></mml:math></alternatives></disp-formula>
</p></sec><sec id="sec2.4"><label>2.4</label><title>Particle Size and Zeta (&#950;) Potential
Measurement</title><p>For the measurement, the NPs were prepared in
pH 7.4 PBS. The particle size, size distribution, and polydispersity
index (PDI) of the NPs were evaluated by using Dynamic Light Scattering
(DLS) with a NanoBrook Omni Particle Analyzer (Brookhaven Instruments
Corporation). Measurements were conducted at 25 &#176;C in a 10 mm
cuvette with detection at a 90&#176; angle. The &#950; potential
was determined by Phase Analysis Light Scattering (PALS) by using
the same machine. Moreover, the change in NPs&#8217; particle sizes
was monitored at different pH levels and temperatures to estimate
NP stability.</p></sec><sec id="sec2.5"><label>2.5</label><title>
<italic toggle="yes">In Vitro</italic> Drug Release Study</title><p>To test the release of CoQ10 from STNPs, the dialysis method was
used. Briefly, the drug-loaded NPs were placed in a dialysis bag (MWCO:
12&#8211;14 kDa). The dialysis bag was immersed in pH 7.4 Tween 80
(0.5%, w/v)-containing PBS to mimic the &#8220;sink&#8221; condition
and subjected to stirring at 37 &#176;C for up to 48 h. Samples were
collected from the outer medium at prescheduled time points. The released
drug was measured at the &#955;<sub>max</sub> of 275 nm by a microplate
reader (Tecan). To study MMP-sensitive drug release, the NPs were
preincubated with 100 &#956;g/mL collagenase IV in a pH 7.4 50 mM
HEPES-buffered saline solution (150 mM NaCl and 10 mM CaCl<sub>2</sub>) at 37 &#176;C for 4 h prior to the study of drug release.<named-content content-type="bibref-group">
<xref rid="ref33" ref-type="bibr"/>,<xref rid="ref34" ref-type="bibr"/>
</named-content> The difference factor (f1) and similarity factor (f<sub>2</sub>)
were calculated to compare the drug release profiles of the free drugs
and NP formulations using DDSolver software.<named-content content-type="bibref-group">
<xref rid="ref45" ref-type="bibr"/>&#8722;<xref rid="ref46" ref-type="bibr" specific-use="suppress-in-print"/>
<xref rid="ref47" ref-type="bibr"/>
</named-content>
</p></sec><sec id="sec2.6"><label>2.6</label><title>PS Exposure/&#8220;Externalization&#8221;
Analysis</title><p>To confirm the MMP sensitivity and PS exposure on
the surface of the NPs, the FITC-labeled annexin V protein was used
as a probe.<xref rid="ref34" ref-type="bibr"/> Briefly, the samples of PS,
PC, and PEG-pp-PE/PS (STNPs) were preincubated with 100 &#956;g/mL
collagenase IV at 37 &#176;C for 4 h. Then, the samples were incubated
with FITC-annexin V in the dark at room temperature for 15 min, followed
by analysis using a BD Accouri C6 flow cytometer.</p></sec><sec id="sec2.7"><label>2.7</label><title>Cellular Uptake Study</title><p>To study cellular
uptake, RAW 264.7 or NIH/3T3 cells were seeded in 96-well plates with
1 &#215; 10<sup>4</sup> cells/well and incubated overnight. To investigate
the impact of MMPs on cellular uptake, the Rh-PE-loaded NPs were prepared
and pretreated with 100 &#956;g/mL collagenase IV at 37 &#176;C in
the dark for 4 h. The cells were treated with the NPs in serum-free
DMEM at 37 &#176;C for 1 h. Then, the cells were rinsed with PBS to
eliminate uninternalized NPs and observed under a Nikon Eclipse Ti
fluorescence microscope. To quantify the uptake, the cells were trypsinized,
collected, and analyzed with a BD Accouri C6 flow cytometer. Viable
cells were distinguished from dead cells and debris based on their
forward versus side scatter characteristics.</p></sec><sec id="sec2.8"><label>2.8</label><title>Cytotoxicity Study</title><p>The cytotoxicity
of the NP formulations was analyzed by the CellTiter-Blue Cell Viability
Assay (Promega). Briefly, the cells (3 &#215; 10<sup>3</sup> cells/well)
were seeded in 96-well plates and incubated overnight before the treatments.
The formulations, including CoQ10, empty STNPs, and CoQ10-loaded STNPs,
were incubated with the cells in complete growth media at 37 &#176;C
for 46 h. Then, 10 &#956;L of CellTiter-Blue reagent was added to
the cells and incubated for an additional 2 h. The fluorescence of
the treated cells was determined at &#955;<sub>ex</sub> of 560 nm
and &#955;<sub>em</sub> of 590 nm using a microplate reader (Tecan).</p></sec><sec id="sec2.9"><label>2.9</label><title>Determination of Cytokine Production</title><p>The cytokine production in the RAW 264.7 cells was determined by
ELISA (eBioscience Inc.) according to the manufacturer&#8217;s manual.
Briefly, the cells (1 &#215; 10<sup>5</sup> cells/well) were seeded
in 12-well plates and incubated overnight before the treatments. In
this experiment, five treatments were evaluated, including: (1) Untreated;
(2) LPS (100 ng/mL) + IFN-&#947; (20 ng/mL) activation; (3) LPS (100
ng/mL) + IFN-&#947; (20 ng/mL) activation, then CoQ10; 4) LPS (100
ng/mL) + IFN-&#947; (20 ng/mL) activation, then CoQ10-loaded STNPs
with MMP pretreatment; and (5) LPS (100 ng/mL) + IFN-&#947; (20 ng/mL)
activation, then CoQ10-loaded STNPs without MMP pretreatment. After
24 h of activation, the cells were incubated with the formulations
for an additional 24 h. Then, the cell medium was collected, followed
by ELISA.</p></sec><sec id="sec2.10"><label>2.10</label><title>Macrophage Surface Marker Analysis</title><p>In this experiment, five treatment groups were evaluated, including:
(1) Untreated; (2) LPS (100 ng/mL) + IFN-&#947; (20 ng/mL) activation;
(3) LPS (100 ng/mL) + IFN-&#947; (20 ng/mL) activation, then CoQ10;
4) LPS (100 ng/mL) + IFN-&#947; (20 ng/mL) activation, then CoQ10-loaded
STNPs with MMP pretreatment; and 5) LPS (100 ng/mL) + IFN-&#947;
(20 ng/mL) activation, then CoQ10-loaded STNPs without MMP pretreatment.
Briefly, the RAW 264.7 cells (1 &#215; 10<sup>5</sup> cells/well)
were seeded in 12-well plates and incubated overnight. The cells were
activated for 24 h, followed by incubation with the formulations for
an additional 24 h. Then, the cells were trypsinized, collected, and
incubated with FITC-labeled antibodies against macrophage surface
markers for 30 min on ice, followed by flow cytometry on a BD Accouri
C6 flow cytometer.</p></sec><sec id="sec2.11"><label>2.11</label><title>Inflammation Inhibition in Cell Co-Cultures</title><p>The macrophages (RAW 264.7) and fibroblasts (NIH/3T3) at 1 &#215;
10<sup>5</sup> cells/well (1:1 ratio) were seeded in 6-well plates
and incubated overnight to generate the cell coculture. To mimic RA
inflammation, the coculture was pretreated with LPS and IFN-&#947;.
Briefly, five treatments were assessed in this model, including: (1)
Untreated; (2) LPS (100 ng/mL) + IFN-&#947; (20 ng/mL) activation;
(3) LPS (100 ng/mL) + IFN-&#947; (20 ng/mL) activation, then CoQ10;
(4) LPS (100 ng/mL) + IFN-&#947; (20 ng/mL) activation, then CoQ10-loaded
STNPs with MMP pretreatment; and (5) LPS (100 ng/mL) + IFN-&#947;
(20 ng/mL) activation, then CoQ10-loaded STNPs without MMP pretreatment.
After 24 h of treatment, the cytokines and cell surface markers were
determined.</p></sec><sec id="sec2.12"><label>2.12</label><title>Macrophage Morphology</title><p>The impact
of the CoQ10 nanomedicine on macrophages&#8217; morphology was also
examined. RAW 264.7 cells were seeded in a 35 mm dish with 14 mm glass
bottom at a density of 1 &#215; 10<sup>5</sup> cells/well and incubated
overnight before the experiments. The cells were preactivated with
LPS (100ng/mL) + IFN-&#947; (20 ng/mL) for 24 h. Then, the cells
were treated with CoQ10-loaded STNPs at 37 &#176;C for 4, 8, or 12
h. The morphological changes in the cells were analyzed by using a
Nikon Eclipse Ti fluorescence microscope.</p></sec><sec id="sec2.13"><label>2.13</label><title>Statistical Analysis</title><p>Three independent
experiments were performed to obtain quantitative data. The data were
expressed as mean &#177; standard deviation.<xref rid="ref48" ref-type="bibr"/> For statistical analysis, the three formulations were analyzed using
one-way ANOVA, while paired <italic toggle="yes">t</italic>-tests were performed
to evaluate differences before and after drug loading within each
formulation. Moreover, the STNPs with and without the MMP pretreatment
were analyzed by unpaired <italic toggle="yes">t</italic>-test using GraphPad Prism
(version 10.4.1) (San Diego, CA, USA). *&#173;(<italic toggle="yes">p</italic> &lt; 0.05),
**&#173;(<italic toggle="yes">p</italic> &lt; 0.01), or ***&#173;(<italic toggle="yes">p</italic> &lt; 0.001)
indicate a statistically significant difference.</p></sec></sec><sec id="sec3"><label>3</label><title>Results and Discussion</title><p>CoQ10 is an
endogenous ubiquinone that is mainly synthesized in
the mitochondrial inner membrane and is present in most cell membranes.<xref rid="ref49" ref-type="bibr"/> CoQ10 is a lipophilic molecule and plays a crucial
role in cellular energy production and many other processes. Among
its many functions, CoQ10 shows its anti-inflammatory effects mainly
by inhibiting inflammation-related genes, e.g., <italic toggle="yes">NF-&#954;B</italic>, and inducing genes that suppress inflammation, e.g., <italic toggle="yes">miR-146-a</italic> and <italic toggle="yes">Nrf2</italic>.<named-content content-type="bibref-group">
<xref rid="ref43" ref-type="bibr"/>,<xref rid="ref44" ref-type="bibr"/>
</named-content> CoQ10 also acts as
a potent antioxidant, preventing cells from oxidative damage caused
by free radicals<xref rid="ref50" ref-type="bibr"/> to prevent or ameliorate
inflammation. However, due to its high lipophilicity, CoQ10 shows
poor water solubility and low bioavailability, even though it can
easily diffuse through cell membranes.<xref rid="ref44" ref-type="bibr"/> This poses a significant challenge in CoQ10&#8217;s formulation
development and clinical applications.<named-content content-type="bibref-group">
<xref rid="ref51" ref-type="bibr"/>,<xref rid="ref52" ref-type="bibr"/>
</named-content> To date ,
numerous efforts have been made to increase CoQ10&#8217; solubility
and bioavailability.</p><p>In our prior research, we synthesized several
MMP2/9-sensitive
copolymers and conjugates and demonstrated their potential in targeted
drug delivery and controlled drug release.<named-content content-type="bibref-group">
<xref rid="ref33" ref-type="bibr"/>,<xref rid="ref35" ref-type="bibr"/>,<xref rid="ref39" ref-type="bibr"/>,<xref rid="ref53" ref-type="bibr"/>,<xref rid="ref54" ref-type="bibr"/>
</named-content> Among them, the MMP2/9-sensitive self-assembling
copolymers, PEG-pp-PE, have been used in the preparation of different
types of nanomedicine with improved tumor specificity and on-demand
drug release.<named-content content-type="bibref-group">
<xref rid="ref33" ref-type="bibr"/>,<xref rid="ref34" ref-type="bibr"/>,<xref rid="ref39" ref-type="bibr"/>,<xref rid="ref40" ref-type="bibr"/>
</named-content> In this work, using the MMP-sensitive copolymer
(PEG-pp-PE) along with the &#8220;eat me&#8221; ligand PS, we prepared
an inflammation- and macrophage-dual-targeting nanocarrier for CoQ10
delivery and RA treatment. In this design, MMP2/9 works as a &#8220;switch&#8221;
to control the transition from &#8220;don&#8217;t eat me&#8221;
(PEG shield) to &#8220;eat me&#8221; (PS exposure) of the CoQ10-loaded
NPs (nanomedicine). In inflamed tissues, the upregulated MMPs cleave
PEG-pp-PE to remove the PEG and expose the PS on the surface of NPs
for macrophage-targeted phagocytosis (<xref rid="fig1" ref-type="fig">Figure <xref rid="fig1" ref-type="fig"/>
</xref>).</p><sec id="sec3.1"><label>3.1</label><title>Nanoparticle Preparation and Drug Loading</title><p>In previous studies, like commercially available PEG-PE polymers,
the MMP-sensitive PEG-pp-PE was able to self-assemble and form polymeric
micelles with a lipid core capable of encapsulating lipophilic drugs.<named-content content-type="bibref-group">
<xref rid="ref39" ref-type="bibr"/>,<xref rid="ref55" ref-type="bibr"/>
</named-content> In this study, the lipid<xref rid="ref14" ref-type="bibr"/> and PEG-pp-PE
together would self-assemble into an NP under mild sonication to form
a similar &#8220;core-shell&#8221; nanostructure with a lipid (PE
+ PS) core and a PEG shell <xref rid="fig2" ref-type="fig">Figure <xref rid="fig2" ref-type="fig"/>
</xref>.</p><fig position="float" id="fig2" fig-type="figure" orientation="portrait"><label>2</label><caption><p>Encapsulation efficiency and drug loading of the PEG-pp-PE/PS
(75/25,
50/50, and 25/75 wt %) self-assembled NPs (STNPs) (mean &#177; SD, <italic toggle="yes">n</italic> = 3). STNP (50/50) was compared with STNP (75/25) and
STNP (25/75). ***<italic toggle="yes">p</italic> &lt; 0.001, statistically significant.</p></caption><graphic id="gr2" position="float" orientation="portrait" xlink:href="mp5c00742_0002.jpg"/></fig><p>Due to its high lipophilicity, CoQ10 is poorly
water-soluble. The
NP formulations with three different PEG-pp-PE/PS ratios were prepared
to examine their drug-loading capability. We found that the lipophilic
CoQ10 was readily incorporated into the lipid core of all PEG-pp-PE/PS
NPs during NP formation (self-assembly), probably through hydrophobic
interactions.<xref rid="ref56" ref-type="bibr"/> Among the formulations,
the STNPs (PEG-pp-PE/PS, 50/50 wt %) showed the highest encapsulation
of 97.46 &#177; 2.37% and drug loading of 9.74 &#177; 0.23%. This
might be due to the excellent self-assembly of PEG-pp-PE and PS at
the ratio of 50/50 and the increased volume of the lipid core (both
PE and PS) of the NPs.</p></sec><sec id="sec3.2"><label>3.2</label><title>Particle Size and Zeta Potential</title><p>The particle size and zeta potential of nanoparticles are crucial
for maintaining colloidal stability by preventing aggregation through
electrostatic repulsion among particles. For drug delivery, the nanoranged
size and proper surface charge can not only help prevent NP aggregation
but also reduce the likelihood of rapid clearance and prolong NPs&#8217; <italic toggle="yes">in vivo</italic> half-life.<xref rid="ref57" ref-type="bibr"/>
</p><p>The
NP&#8217;s particle size was evaluated by DLS (<xref rid="fig3" ref-type="fig">Figure <xref rid="fig3" ref-type="fig"/>
</xref>). The mean particle size of the empty NPs
ranged from 146.83 &#177; 3.21 nm to 178.00 &#177; 5.71 nm. The CoQ10
loading changed the particle sizes of the NPs; however, the particle
sizes of the drug-loaded NPs remained within the range of 100&#8211;200
nm, which is considered appropriate for drug delivery.<named-content content-type="bibref-group">
<xref rid="ref58" ref-type="bibr"/>&#8722;<xref rid="ref59" ref-type="bibr" specific-use="suppress-in-print"/>
<xref rid="ref60" ref-type="bibr"/>
</named-content>
</p><fig position="float" id="fig3" fig-type="figure" orientation="portrait"><label>3</label><caption><p>Mean
particle size of self-assembled PEG-pp-PE/PS NPs (STNPs) at
pH 7.4 with or without loading of CoQ10 (mean &#177; SD, <italic toggle="yes">n</italic> = 3). ns, not statistically significant; ***<italic toggle="yes">p</italic> &lt;
0.001, statistically significant.</p></caption><graphic id="gr3" position="float" orientation="portrait" xlink:href="mp5c00742_0003.jpg"/></fig><p>Among the STNP formulations, STNPs (50/50) with
or without CoQ10
showed a similar mean particle size (<xref rid="fig3" ref-type="fig">Figure <xref rid="fig3" ref-type="fig"/>
</xref>) and size distribution, which might indicate
their stable nanostructure (<xref rid="fig4" ref-type="fig">Figure <xref rid="fig4" ref-type="fig"/>
</xref>A). The PDI data for empty and CoQ10-loaded NPs ranged
from 0.089 &#177; 0.024 to 0.369 &#177; 0.086 (<xref rid="fig4" ref-type="fig">Figure <xref rid="fig4" ref-type="fig"/>
</xref>B), indicating a homogeneous distribution
of NPs with respect to their particle size and stability.<named-content content-type="bibref-group">
<xref rid="ref14" ref-type="bibr"/>,<xref rid="ref61" ref-type="bibr"/>,<xref rid="ref62" ref-type="bibr"/>
</named-content> Among the formulations, STNPs
(50/50) showed the lowest PDI. Also, considering the highest drug
loading and encapsulation of STNPs (50/50) (<xref rid="fig2" ref-type="fig">Figure <xref rid="fig2" ref-type="fig"/>
</xref>), the formulation STNPs (50/50) was selected
for further experiments, although their particle size with the drug
(175.94 &#177; 3.43 nm) was slightly larger than that of other formulations.</p><fig position="float" id="fig4" fig-type="figure" orientation="portrait"><label>4</label><caption><p>Particle
size distribution (A) and PDI (B) of empty STNPs and CoQ10-loaded
STNPs (mean &#177; SD, <italic toggle="yes">n</italic> = 3). STNP (50/50) was compared
with STNP (75/25) and STNP (25/75). ***<italic toggle="yes">p</italic> &lt; 0.001,
statistically significant.</p></caption><graphic id="gr4" position="float" orientation="portrait" xlink:href="mp5c00742_0004.jpg"/></fig><p>All of the empty NPs and drug-loaded NPs showed
a similar zeta
potential, ranging from &#8722;38.25 &#177; 0.827 to &#8722;43.50
&#177; 3.33 (<xref rid="fig5" ref-type="fig">Figure <xref rid="fig5" ref-type="fig"/>
</xref>). The CoQ10 loading did not have a significant impact on the zeta
potential of the NPs. The NPs&#8217; negative zeta potential might
be due to the high content of PS, which is negatively charged at physiological
pH.<named-content content-type="bibref-group">
<xref rid="ref15" ref-type="bibr"/>,<xref rid="ref16" ref-type="bibr"/>
</named-content> The negative charge enhances the repulsion
among NPs, preventing the formation of large aggregates, i.e., ensuring
the stability of the NPs. The data were confirmed by NPs&#8217; nanoscale
size and low PDI (<xref rid="fig3" ref-type="fig">Figures <xref rid="fig3" ref-type="fig"/>
</xref> and <xref rid="fig4" ref-type="fig"/>).</p><fig position="float" id="fig5" fig-type="figure" orientation="portrait"><label>5</label><caption><p>Zeta potential of empty
NPs (STNPs) and CoQ10-loaded STNPs (mean
&#177; SD, <italic toggle="yes">n</italic> = 3). ns, not statistically significant.</p></caption><graphic id="gr5" position="float" orientation="portrait" xlink:href="mp5c00742_0005.jpg"/></fig><p>Here, the NPs/nanomedicines were prepared via self-assembly
by
using the conventional thin-film hydration method. We noticed that
several NP parameters changed, including drug loading, particle size,
zeta potential, PDI, etc., when the ratio of the NPs&#8217; components
was changed. This may be due to several factors related to polymer
and lipid self-assembly, nanoparticle formation, and drug-lipid interactions.<named-content content-type="bibref-group">
<xref rid="ref63" ref-type="bibr"/>,<xref rid="ref64" ref-type="bibr"/>
</named-content> At different ratios, the required numbers of the &#8220;monomers&#8221;
(i.e., polymers and lipids) to form an NP may not be the same, which
could influence the NP parameters. After loading hydrophobic/lipophilic
CoQ10, the drug&#58872;lipid/polymer interaction may influence nanoparticle
packing, which might also change NPs&#8217; particle size and zeta
potential.</p></sec><sec id="sec3.3"><label>3.3</label><title>Sustained Drug Release</title><p>The <italic toggle="yes">in vitro</italic> drug release rate of the STNPs was determined by
using a dialysis method. The drug release profile of the free CoQ10
and CoQ10-loaded STNPs, with or without MMPs, is shown in <xref rid="fig6" ref-type="fig">Figure <xref rid="fig6" ref-type="fig"/>
</xref>. The free CoQ10
showed a rapid release, with more than 50% of the drug released within
the initial 2 h due to the dissolution and diffusion behavior of free
CoQ10. In contrast, the NPs demonstrated a sustained drug release
pattern. To further analyze the data, the difference factor (f<sub>1</sub>) and similarity factor (f<sub>2</sub>) were calculated (Tables
S1 and S2), as recommended by the Food and Drug Administration to
assess the similarity of the dissolution profiles between formulations.
The f1 values ranging from 0 to 15 and f2 values from 50 to 100 shows
that similarity exists between two profiles.<named-content content-type="bibref-group">
<xref rid="ref45" ref-type="bibr"/>&#8722;<xref rid="ref46" ref-type="bibr" specific-use="suppress-in-print"/>
<xref rid="ref200" ref-type="bibr"/>
</named-content> The f<sub>1</sub> values for CoQ10 vs CoQ10-loaded STNPs (+MMPs and &#8722;MMPs)
were 41.43 and 42.46, respectively, which are more than 15, indicating
different drug release profiles. In contrast, the f<sub>1</sub> value
for CoQ10-loaded STNPs + MMPs vs CoQ10-loaded STNPs&#8211;MMPs was
7.97, which is less than 15, indicating no significant difference.
The f<sub>2</sub> values for CoQ10 vs CoQ10-loaded STNPs (+MMPs and
&#8722;MMPs) were 33.76 and 33.57, respectively, which are less than
50, confirming dissimilarity, while the f<sub>2</sub> value for CoQ10-loaded
STNPs + MMPs vs CoQ10-loaded STNPs&#8211;MMPs was 76.97, which is
more than 50, indicating similar drug release profiles.<named-content content-type="bibref-group">
<xref rid="ref45" ref-type="bibr"/>,<xref rid="ref46" ref-type="bibr"/>
</named-content>
</p><fig position="float" id="fig6" fig-type="figure" orientation="portrait"><label>6</label><caption><p>Drug
release of CoQ10-loaded STNPs determined by a dialysis method
under the &#8220;sink&#8221; condition (mean &#177; SD, <italic toggle="yes">n</italic> = 3). <italic toggle="yes">ns</italic>, not statistically significant.</p></caption><graphic id="gr6" position="float" orientation="portrait" xlink:href="mp5c00742_0006.jpg"/></fig><p>The NPs&#8217; sustained CoQ10 release profiles
confirmed the
core&#8211;shell-structured NPs&#8217; excellent drug-loading capability
and stability.<named-content content-type="bibref-group">
<xref rid="ref65" ref-type="bibr"/>,<xref rid="ref66" ref-type="bibr"/>
</named-content> The NPs, with or without MMP
preincubation, showed almost the same drug release pattern, indicating
that the influence of MMPs on drug release was negligible. This would
ensure the stability of CoQ10-loaded NPs during drug delivery for
macrophage-specific phagocytosis in inflamed tissues, minimizing undesirable
side effects associated with &#8220;premature&#8221; drug release
or leakage and providing more controlled and precise therapeutic effects
in treating RA.</p></sec><sec id="sec3.4"><label>3.4</label><title>Stability of Nanoparticles at Different pHs
and Temperatures</title><p>The stability of NPs was also evaluated
through the measurement of particle sizes at different pH values and
temperatures (<xref rid="fig7" ref-type="fig">Figure <xref rid="fig7" ref-type="fig"/>
</xref>). In RA, along with disease progression, the pH in inflamed tissues
decreases. In this experiment, the pH of the PBS was adjusted from
7.4 to 5.5 to represent the pH of normal tissues, inflamed tissues,
and endo/lysosomes in RA.<named-content content-type="bibref-group">
<xref rid="ref67" ref-type="bibr"/>&#8722;<xref rid="ref68" ref-type="bibr" specific-use="suppress-in-print"/>
<xref rid="ref69" ref-type="bibr" specific-use="suppress-in-print"/>
<xref rid="ref70" ref-type="bibr" specific-use="suppress-in-print"/>
<xref rid="ref71" ref-type="bibr"/>
</named-content> The NPs were also incubated at 4 &#176;C (simulatingfor storage
conditions), 25 &#176;C (room temperature handling), or 37 &#176;C
(drug administration) for 72 h. Though particle sizes of the NPs were
slightly changed under different conditions, they were in the proper
nanoscale range, indicating NPs&#8217; great colloidal stability
during preparation, storage, and administration, most likely due to
effective surface stabilization and steric repulsion.</p><fig position="float" id="fig7" fig-type="figure" orientation="portrait"><label>7</label><caption><p>Particle size distribution
of the STNPs at different pH values
(A) and temperatures (B).</p></caption><graphic id="gr7" position="float" orientation="portrait" xlink:href="mp5c00742_0007.jpg"/></fig></sec><sec id="sec3.5"><label>3.5</label><title>MMP-Dependent PS Exposure/&#8220;Externalization&#8221;</title><p>The MMP-sensitive PS exposure is critical to triggering effective
phagocytosis in RA with MMP overexpression. To assess the MMP sensitivity
and PS exposure, the STNPs were incubated with FITC-labeled annexin
V, a commonly used probe for the detection of PS externalization in
apoptotic cells. The binding affinity between the exposed PS and FITC-annexin
V was examined by using flow cytometry. In this experiment, the PS
NPs, having a strong binding affinity with FITC-annexin V, were used
to represent the NPs with fully exposed PS. The PC NPs, showing low
binding with FITC-annexin V, were used to represent the NPs with fully
hidden PS. The STNPs were also tested in the presence or absence of
MMPs.</p><p>The PEG-shielded (PS-hidden) STNPs had a low level of
annexin V binding, comparable to the PC NPs, due to the PEG&#8217;s
&#8220;stealth&#8221; effect. In contrast, the STNPs with the MMP
preincubation showed a remarkably higher level of annexin V binding
(<xref rid="fig8" ref-type="fig">Figure <xref rid="fig8" ref-type="fig"/>
</xref>), suggesting
that MMPs could effectively cleave PEG-pp-PE and expose the PS on
the NPs. The results indicated that PS exposure on the surface of
the NPs could be triggered and controlled by the MMPs.</p><fig position="float" id="fig8" fig-type="figure" orientation="portrait"><label>8</label><caption><p>MMP-dependent PS exposure.
The binding between FITC-Annexin V and
NPs&#8217; PS was analyzed by flow cytometry (mean &#177; SD, <italic toggle="yes">n</italic> = 3). STNPs were preincubated with MMPs at 37 &#176;C
for 4 h. ***<italic toggle="yes">p</italic> &lt; 0.001, statistically significant.</p></caption><graphic id="gr8" position="float" orientation="portrait" xlink:href="mp5c00742_0008.jpg"/></fig></sec><sec id="sec3.6"><label>3.6</label><title>MMP-Sensitive Cellular Uptake and Selectivity</title><p>To study the MMP sensitivity, the NPs were pretreated with the
MMPs, followed by phagocytosis studies in mouse macrophages (RAW264.7).
We found that the STNPs showed a significant increase in their uptake
by macrophages in the presence of the MMPs compared to their counterparts
in the absence of the MMPs (<xref rid="fig9" ref-type="fig">Figure <xref rid="fig9" ref-type="fig"/>
</xref>). In contrast, both the MMP-sensitive, macrophage-nontargeting
SNNPs (PEG-pp-PE/PC) and the nonsensitive, macrophage-targeting NTNPs
(PEG-PE/PS) showed negligible cellular uptake regardless of whether
they were preincubated with the MMPs or not.</p><fig position="float" id="fig9" fig-type="figure" orientation="portrait"><label>9</label><caption><p>MMP2-sensitive cellular
uptake of Rh-PE-loaded NPs in RAW 264.7
macrophages. <bold>STNPs</bold>, MMP-<underline>
<bold>S</bold>
</underline>ensitive macrophage <underline>
<bold>T</bold>
</underline>argeting
PEG-pp-PE/PS <underline>
<bold>NPs</bold>
</underline>; <bold>SNNPs</bold>, MMP-<bold>S</bold>ensitive macrophage <underline>
<bold>N</bold>
</underline>ontargeting PEG-pp-PE/PC <underline>
<bold>NPs</bold>
</underline>; <bold>NTNPs</bold>, <underline>
<bold>N</bold>
</underline>onsensitive
macrophage <underline>
<bold>T</bold>
</underline>argeting PEG-PE/PS <underline>
<bold>NPs</bold>
</underline>. The NPs were preincubated with or without
MMPs for 4 h, followed by 1-h cell incubation. The treated cells were
examined with a fluorescence microscope.</p></caption><graphic id="gr9" position="float" orientation="portrait" xlink:href="mp5c00742_0009.jpg"/></fig><p>PEGylation is a well-known strategy to decrease
NPs&#8217; nonspecific
interaction and increase NPs&#8217; stability. Methoxy PEGs (mPEG)
generally exhibit a slightly negative to neutral surface charge. The
PEGylated NPs may be neutral if the PEG length and intensity are appropriate.
However, even when charged, the PEGylated NPs could increase drugs&#8217;
specificity and decrease nonspecific uptake/biodistribution in many
applications, including RA,<xref rid="ref72" ref-type="bibr"/> cancer,<named-content content-type="bibref-group">
<xref rid="ref34" ref-type="bibr"/>,<xref rid="ref73" ref-type="bibr"/>,<xref rid="ref74" ref-type="bibr"/>
</named-content> etc. Our results suggested that
the &#8220;stealth&#8221; PEG-PE (or intact PEG-pp-PE) could &#8220;mask&#8221;
the PS and inhibit phagocytosis of PEGylated NPs. Upon MMP preincubation,
the peptide linker (pp) of PEG-pp-PE was cleaved, leading to STNPs&#8217;
PEG deshielding and PS exposure. The PS-exposed NPs, acting as an
&#8220;eat-me&#8221; signal, effectively triggered phagocytosis
by macrophages. The data also suggested that when used alone, the
MMP-sensitive PEG shielding/deshielding strategy (SNNPs) or the PS
exposure for &#8220;eat-me&#8221; strategy (NTNPs) might not be
effective for targeting macrophages in inflammation.</p><p>To evaluate
the NPs&#8217; cell selectivity, we compared the NP
uptake in both macrophages (RAW264.7) and fibroblasts (NIH3T3) with
or without MMP preincubation (<xref rid="fig10" ref-type="fig">Figure <xref rid="fig10" ref-type="fig"/>
</xref>A). In NIH3T3 cells, most NPs, including PS NPs, had
mild to low cellular uptake, and the STNPs showed no MMP responsiveness.
The NPs with the exposed PS upon MMP preincubation failed to increase
the cellular uptake, suggesting that PS was not a favorable factor
for promoting NP internalization in NIH3T3 fibroblasts. However, under
the same conditions, all NPs showed enhanced cellular uptake in RAW264.7
macrophages. Notably, the cellular uptake of MMP-preincubated STNPs
in RAW264.7 cells was about 13-fold higher than that in NIH3T3 cells.
Even without MMP preincubation, the STNPs still exhibited higher uptake
in macrophages than in fibroblasts, possibly due to the endogenous
MMPs produced by macrophages.<xref rid="ref28" ref-type="bibr"/> Additionally,
the uptake of the MMP-preincubated STNPs in macrophages was approximately
75-fold higher than the untreated group, while the uptake of the same
formulations in fibroblasts was only approximately 6-fold higher than
the untreated group (<xref rid="fig10" ref-type="fig">Figure <xref rid="fig10" ref-type="fig"/>
</xref>B). All these data suggest that the STNPs are MMP-sensitive
and macrophage-selective nanocarriers.</p><fig position="float" id="fig10" fig-type="figure" orientation="portrait"><label>10</label><caption><p>Cell selectivity of
the Rh-PE-loaded NPs analyzed by fluorescence
microscopy (A) and flow cytometry (B). <bold>STNPs</bold>, MMP-<underline>
<bold>S</bold>
</underline>ensitive macrophage <underline>
<bold>T</bold>
</underline>argeting PEG-pp-PE/PS <underline>
<bold>NPs</bold>
</underline>; <bold>SNNPs</bold>, MMP-<bold>S</bold>ensitive macrophage <underline>
<bold>N</bold>
</underline>ontargeting PEG-pp-PE/PC <underline>
<bold>NPs</bold>
</underline>; <bold>NTNPs</bold>, <underline>
<bold>N</bold>
</underline>onsensitive macrophage <underline>
<bold>T</bold>
</underline>argeting PEG-PE/PS <underline>
<bold>NPs</bold>
</underline>. The NPs
were preincubated with or without MMPs for 4 h, followed by 1-h incubation
with macrophages (RAW 264.7) and fibroblasts (NIH/3T3) (mean &#177;
SD, <italic toggle="yes">n</italic> = 3). <italic toggle="yes">ns</italic>, not statistically
significant; ***<italic toggle="yes">p</italic> &lt; 0.001, statistically significant.</p></caption><graphic id="gr10" position="float" orientation="portrait" xlink:href="mp5c00742_0010.jpg"/></fig></sec><sec id="sec3.7"><label>3.7</label><title>Cytotoxicity Assessment</title><p>The cytotoxicity
of the STNPs loaded with CoQ10 was assessed in RAW 264.7 cells by
the CellTiter-Blue Cell Viability Assay. The empty STNPs, free CoQ10,
and CoQ10-loaded STNPs were tested at drug concentrations of 0.01&#8211;10
&#956;g/mL. The typical human body contains 0.5&#8211;1.5 &#956;g/mL
of CoQ10, while disease-related conditions usually lower the CoQ10
concentration. Daily CoQ10 supplementation in the range of 100&#8211;300
mg can increase plasma CoQ10 levels to 2&#8211;5 &#956;g/mL, whereas
taking 1200 mg of CoQ10 per day may raise plasma concentrations to
around 10 &#956;g/mL.<named-content content-type="bibref-group">
<xref rid="ref75" ref-type="bibr"/>,<xref rid="ref76" ref-type="bibr"/>
</named-content> The tested CoQ10 concentrations
in this study were clinically relevant.</p><p>After 48 h of treatment,
no significant changes in cell viability were detected in any of the
tested formulations compared to the untreated cells (<xref rid="fig11" ref-type="fig">Figure <xref rid="fig11" ref-type="fig"/>
</xref>). The data suggested that
both CoQ10 and CoQ10-loaded NPs were not toxic, even at high concentrations,
in agreement with previous reports.<named-content content-type="bibref-group">
<xref rid="ref77" ref-type="bibr"/>,<xref rid="ref78" ref-type="bibr"/>
</named-content> This was not
surprising because (i) CoQ10 is found in almost every cell in the
human body and has been demonstrated to be safe as a dietary supplement,<xref rid="ref79" ref-type="bibr"/> and (ii) the STNPs&#8217; building materials
are safe and have been widely used in drug formulations and delivery
systems.<named-content content-type="bibref-group">
<xref rid="ref34" ref-type="bibr"/>,<xref rid="ref39" ref-type="bibr"/>,<xref rid="ref66" ref-type="bibr"/>
</named-content>
</p><fig position="float" id="fig11" fig-type="figure" orientation="portrait"><label>11</label><caption><p>Cytotoxicity
of free CoQ10, empty STNPs (100 &#956;g/mL), and
CoQ10-loaded STNPs. Cell incubation time: 48 h.</p></caption><graphic id="gr11" position="float" orientation="portrait" xlink:href="mp5c00742_0011.jpg"/></fig></sec><sec id="sec3.8"><label>3.8</label><title>Inhibition of Inflammation by CoQ10-Loaded
STNPs</title><p>In this work, we aimed to increase not only the bioavailability
but also the specificity of CoQ10 by a novel nanoformulation to improve
its anti-inflammatory activities and reduce its required doses. In
this experiment, LPS+IFN-&#947; preincubation dramatically increased
the production of inflammatory cytokines in macrophages, including
TNF-&#945; by approximately 7.5-fold, IL-6 by approximately 9-fold,
and IL-1&#946; by approximately 6.3-fold, as compared to untreated
cells (<xref rid="fig12" ref-type="fig">Figure <xref rid="fig12" ref-type="fig"/>
</xref>).
In the LPS+IFN-&#947;-stimulated macrophages, free CoQ10 significantly
decreased the levels of pro-inflammatory cytokines (TNF-&#945; by
approximately 4.6-fold, IL-6 by approximately 5.4-fold, and IL-1&#946;
by approximately 5-fold, compared to untreated cells), confirming
its anti-inflammatory effects. We found that the CoQ10-loaded STNPs
showed effects similar to those of free CoQ10 without MMP preincubation.
However, after MMP preincubation, the CoQ10-loaded STNPs further reduced
the TNF-&#945; level to approximately 2.5-fold, the IL-6 level to
approximately 3-fold, and the IL-1&#946; level to approximately 3.1-fold,
compared to untreated cells.</p><fig position="float" id="fig12" fig-type="figure" orientation="portrait"><label>12</label><caption><p>Inflammatory cytokines. The pro-inflammatory
cytokines including
TNF-&#945;, IL-6, and IL-1&#946; (A) and the anti-inflammatory cytokine,
IL-10 (B) were determined by ELISA. RAW 264.7 cells were preincubated
with LPS and IFN-&#947; for 24 h for activation, followed by various
treatments for an additional 24 h. NPs&#8217; MMP-preincubation time:
4 h. All results were shown as fold changes over untreated cells (mean
&#177; SD, <italic toggle="yes">n</italic> = 3). ***<italic toggle="yes">p</italic> &lt; 0.001,
statistically significant.</p></caption><graphic id="gr12" position="float" orientation="portrait" xlink:href="mp5c00742_0012.jpg"/></fig><p>To confirm the NPs&#8217; effects on inflammation,
the anti-inflammatory
cytokine IL-10 was also measured in the LPS+IFN-&#947;-stimulated
macrophages. Here, IL-4, which is well-known to promote IL-10 production,
was used as a positive control. We found that free CoQ10 could increase
the IL-10 level, which was similar to the IL-4 treatment.<xref rid="ref80" ref-type="bibr"/> With MMP preincubation, the CoQ10-loaded STNPs
significantly increased the IL-10 level compared to the NPs without
MMP preincubation.</p><p>CoQ10 has been used to deal with inflammation
in RA,<named-content content-type="bibref-group">
<xref rid="ref81" ref-type="bibr"/>,<xref rid="ref82" ref-type="bibr"/>
</named-content> but free CoQ10&#8217;s anti-inflammatory
activities were moderate.
All these results suggested that the STNPs could significantly improve
the efficacy of CoQ10, and the CoQ10-loaded STNPs could effectively
inhibit the production of pro-inflammatory cytokines while enhancing
the production of anti-inflammatory cytokines in response to MMPs.
Our strategy could improve both drug solubility and macrophage targetability/phagocytosis,
thereby optimizing the therapeutic anti-inflammatory effects of CoQ10
in treating RA.</p><p>To confirm the effects of CoQ10 formulations
on inflammation, the
macrophage surface markers, including CD80, CD86, MHC II, and CD206,
were analyzed by corresponding antibodies and flow cytometry.<xref rid="ref83" ref-type="bibr"/> The overexpression of CD80, CD86, and MHC II
indicates the macrophages&#8217; pro-inflammatory polarization, while
the overexpression of CD206 signifies that macrophages are polarized
toward suppression of inflammation. In the experiment, free CoQ10
could only moderately downregulate CD80 and MHC II, but not CD86,
in the stimulated macrophages (<xref rid="fig13" ref-type="fig">Figure <xref rid="fig13" ref-type="fig"/>
</xref>). Loading CoQ10 into the STNPs increased
CoQ10&#8217;s inhibitory effects compared to free CoQ10. The strongest
inhibitory effects were observed with the MMP-pretreated CoQ10-loaded
STNPs, which is in line with the cytokine production data (<xref rid="fig12" ref-type="fig">Figure <xref rid="fig12" ref-type="fig"/>
</xref>). All CoQ10 formulations
and IL-4 treatment substantially increased CD206 expression, with
no significant differences observed among them, indicating the anti-inflammatory
effects of these CoQ10-containing formulations. However, STNPs did
not significantly increase CD206 expression upon MMP preincubation,
which requires further investigation. Overall, the macrophage surface
marker data confirmed that the STNPs could improve CoQ10&#8217;s
anti-inflammatory effects, and these effects were MMP-sensitive.</p><fig position="float" id="fig13" fig-type="figure" orientation="portrait"><label>13</label><caption><p>Macrophage
surface markers. The pro-inflammatory markers, including
CD80, CD86, and MHC II (A), and the anti-inflammatory marker CD206
(B), were analyzed by corresponding antibodies using flow cytometry.
RAW 264.7 cells were preincubated with LPS and IFN-&#947; for 24
h for activation, followed by treatments for an additional 24 h. NPs&#8217;
MMP-preincubation time: 4 h. All results were shown as fold changes
over untreated cells (mean &#177; SD, <italic toggle="yes">n</italic> = 3). <italic toggle="yes">ns</italic>, not statistically significant; *<italic toggle="yes">p</italic> &lt;
0.05 and **<italic toggle="yes">p</italic> &lt; 0.01, statistically significant.</p></caption><graphic id="gr13" position="float" orientation="portrait" xlink:href="mp5c00742_0013.jpg"/></fig><p>To further evaluate the macrophage-selective anti-inflammatory
effects of the CoQ10 nanomedicine, the macrophage/fibroblast cell
coculture model was established. The expression of the pro-inflammatory
cytokines TNF-&#945; and IL-1&#946;, as well as the surface markers
CD80 and CD86, was analyzed. All CoQ10 treatments showed relatively
lower therapeutic effects in the cell cocultures than in macrophages
(<xref rid="fig14" ref-type="fig">Figure <xref rid="fig14" ref-type="fig"/>
</xref>); however,
the trends of the effects were similar. The free CoQ10 could only
moderately inhibit inflammation. The MMP-pretreated CoQ10-loaded STNPs
showed improved anti-inflammatory activity compared to the NPs without
MMP pretreatment. The results suggested that the CoQ10-loaded STNPs
could respond to the MMPs to selectively deliver CoQ10 to macrophages
in the cell cocultures.</p><fig position="float" id="fig14" fig-type="figure" orientation="portrait"><label>14</label><caption><p>Cytokines and macrophage surface markers in
the macrophage/fibroblast
cell cocultures. The pro-inflammatory cytokines, including TNF-&#945;
and IL-1&#946; (A), and cell surface markers, CD80 and CD86 (B),
were analyzed by ELISA and flow cytometry. The cocultures were preincubated
with LPS and IFN-&#947; for 24 h to mimic RA inflammation, followed
by treatments for an additional 24 h. NPs&#8217; MMP preincubation
time: 4 h. All results were presented as fold changes over untreated
cells (mean &#177; SD, <italic toggle="yes">n</italic> = 3). <italic toggle="yes">ns</italic>, not statistically significant; *<italic toggle="yes">p</italic> &lt; 0.05 and
**<italic toggle="yes">p</italic> &lt; 0.01, statistically significant.</p></caption><graphic id="gr14" position="float" orientation="portrait" xlink:href="mp5c00742_0014.jpg"/></fig><p>The impact of CoQ10-loaded STNPs on macrophage
activation was also
examined by cells&#8217; morphology. After 24-h activation by LPS
and IFN-&#947;, the RAW 264.7 cells displayed a significant extension
of pseudopodia, which are temporary, arm-like projections of the cell
membrane that play a crucial role in phagocytosis.<xref rid="ref84" ref-type="bibr"/> The number and length of pseudopodia extensions notably
increased with the duration of activation. Upon treatment with CoQ10-loaded
STNPs, the pseudopodial extensions of the activated macrophages were
inhibited. The effects of CoQ10-loaded STNPs were dose-dependent,
and at a CoQ10 dose of 2.5 &#956;g/mL, the LPS+IFN-&#947;-induced
pseudopodia extensions had almost completely disappeared in macrophages,
resembling those of untreated normal cells (without activation) (<xref rid="fig15" ref-type="fig">Figure <xref rid="fig15" ref-type="fig"/>
</xref>). In contrast,
macrophages treated with 2.5 &#956;g/mL free CoQ10 largely retained
intact pseudopodial extensions, mirroring the morphology of the activated
macrophages. The improved activity of CoQ10-loaded STNPs was mainly
attributed to the increased drug solubility and enhanced phagocytosis.
The data were consistent with the macrophages&#8217; cytokine production
and surface marker expression.</p><fig position="float" id="fig15" fig-type="figure" orientation="portrait"><label>15</label><caption><p>Macrophage morphological changes. RAW
264.7 cells were preactivated
with LPS + IFN-&#947; for 24 h, followed by incubation with CoQ10-loaded
STNPs at CoQ10 doses of 0, 1.25, or 2.5 &#956;g/mL for up to 12 h.</p></caption><graphic id="gr15" position="float" orientation="portrait" xlink:href="mp5c00742_0015.jpg"/></fig><p>Macrophages serve as the front line of the immune
defense and are
integral to numerous physiological and pathological processes. Macrophages
can identify invaders like bacteria and viruses, dead cells, and debris,
as well as foreign substances such as biomaterials and NPs. Specific
molecular patterns act as signals for macrophages to engulf and clear
out pathogens. In the inflamed synovium, in addition to immune cells
(macrophages and T cells), fibroblasts (fibroblast-like synoviocytes)
are a major cell type.<xref rid="ref85" ref-type="bibr"/> Elevated levels
of pro-inflammatory cytokines and enzymes, including MMPs such as
MMP2 and MMP9,<xref rid="ref6" ref-type="bibr"/> have also been found in
inflamed tissues. Although these MMPs may also exist in normal tissues
and organs such as the liver, spleen, etc., their expression and activity
are usually low compared to the MMPs in inflamed joints in RA.<named-content content-type="bibref-group">
<xref rid="ref86" ref-type="bibr"/>&#8722;<xref rid="ref87" ref-type="bibr" specific-use="suppress-in-print"/>
<xref rid="ref88" ref-type="bibr"/>
</named-content> Additionally, the Enhanced Permeability and Retention (EPR) effect
is prominent in inflamed tissues,<xref rid="ref13" ref-type="bibr"/> which
facilitates the passive accumulation of NPs in the joints of RA patients.<xref rid="ref89" ref-type="bibr"/> Accordingly, several MMP2/9-responsive NP systems,
such as liposomes and micelles, have been developed for treating inflammatory
diseases such RA.<named-content content-type="bibref-group">
<xref rid="ref38" ref-type="bibr"/>,<xref rid="ref89" ref-type="bibr"/>
</named-content> However, these drug delivery
systems were not macrophage-specific. In our design, the NPs&#8217;
MMP-sensitive PS exposure worked as an &#8220;eat me&#8221; signal,
leading to phagocytosis by macrophages rather than nonphagocytic cells,
such as fibroblasts. The STNPs&#8217; ability to target inflammation-associated
macrophages can increase the precision of drug delivery, which may
decrease CoQ10 doses, enhance CoQ10&#8217;s therapeutic effects,
and minimize off-target adverse effects for effective RA treatment.<named-content content-type="bibref-group">
<xref rid="ref90" ref-type="bibr"/>,<xref rid="ref91" ref-type="bibr"/>
</named-content>
</p></sec></sec><sec id="sec4"><label>4</label><title>Conclusion</title><p>In this study, we prepared
a smart nanomedicine for the targeted
delivery of CoQ10 to inflammation-associated macrophages. The prepared
nanomedicine demonstrated high CoQ10 loading, excellent physicochemical
properties, and sustained drug release. The nanomedicine was safe
and showed efficient, MMP-dependent cellular uptake in macrophages
rather than in nonphagocytic cells. In macrophages activated by LPS
and IFN-&#947;, the CoQ10 nanomedicine significantly reduced the
levels of pro-inflammatory cytokines and macrophage activation markers
while elevating the levels of anti-inflammatory cytokines and macrophage
markers, leading to effective inhibition of inflammation. Our results
suggest that the developed MMP-sensitive macrophage-targeted CoQ10
nanomedicine has great potential for RA treatment.</p></sec><sec sec-type="supplementary-material"><title>Supplementary Material</title><supplementary-material id="sifile1" position="float" content-type="local-data" orientation="portrait"><media xlink:href="mp5c00742_si_001.pdf" position="float" orientation="portrait"/></supplementary-material></sec></body><back><ack id="ack1"><p>This work was partially supported by the Assistant
Secretary of Defense for Health Affairs, endorsed by the Department
of Defense, in the total amount of $303,000 through the Peer Reviewed
Medical Research Program under Award Number (#HT9425-23-1-0119). Opinions,
interpretations, conclusions, and recommendations contained herein
are those of the authors and are not necessarily endorsed by the Department
of Defense. The work was also partially supported by the Texas A&amp;M
University Health Science Seedling Grant.</p></ack><notes id="notes5" notes-type="si"><p>The Supporting Information is
available free of charge at <ext-link xlink:href="https://pubs.acs.org/doi/10.1021/acs.molpharmaceut.5c00742?goto=supporting-info" ext-link-type="uri">https://pubs.acs.org/doi/10.1021/acs.molpharmaceut.5c00742</ext-link>.<list list-type="simple" id="silist"><list-item><p>Difference factor (f1) and similarity factor (f2) <ext-link xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.molpharmaceut.5c00742/suppl_file/mp5c00742_si_001.pdf" ext-link-type="uri">(PDF)</ext-link>
</p></list-item></list>
</p></notes><notes id="notes1" notes-type="author-contributions"><label>#</label><p>A.A. and N.A. contributed equally to this work.</p></notes><notes id="notes2" notes-type="conflict-of-interest"><p>The authors
declare no competing financial interest.</p></notes><ref-list><ref id="ref1"><element-citation publication-type="journal" id="cit1"><name name-style="western"><surname>Neog</surname><given-names>M. K.</given-names></name><name name-style="western"><surname>Rasool</surname><given-names>M.</given-names></name><article-title>Targeted delivery of p-coumaric acid encapsulated mannosylated
liposomes to the synovial macrophages inhibits osteoclast formation
and bone resorption in the rheumatoid arthritis animal model</article-title><source>Eur. J. Pharm. Biopharm.</source><year>2018</year><volume>133</volume><fpage>162</fpage><lpage>175</lpage><pub-id pub-id-type="doi">10.1016/j.ejpb.2018.10.010</pub-id><pub-id pub-id-type="pmid">30339889</pub-id></element-citation></ref><ref id="ref2"><element-citation publication-type="journal" id="cit2"><name name-style="western"><surname>Burmester</surname><given-names>G. R.</given-names></name><name name-style="western"><surname>Stuhlm&#252;ller</surname><given-names>B.</given-names></name><name name-style="western"><surname>Keyszer</surname><given-names>G.</given-names></name><name name-style="western"><surname>Kinne</surname><given-names>R. W.</given-names></name><article-title>Mononuclear phagocytes
and rheumatoid synovitis. Mastermind or workhorse in arthritis?</article-title><source>Arthritis Rheum.: Off. J. Am. Coll. Rheumatol.</source><year>1997</year><volume>40</volume><issue>1</issue><fpage>5</fpage><lpage>18</lpage><pub-id pub-id-type="doi">10.1002/art.1780400104</pub-id><pub-id pub-id-type="pmid">9008595</pub-id></element-citation></ref><ref id="ref3"><element-citation publication-type="journal" id="cit3"><name name-style="western"><surname>Murray</surname><given-names>P. J.</given-names></name><name name-style="western"><surname>Wynn</surname><given-names>T. A.</given-names></name><article-title>Obstacles and opportunities
for understanding macrophage
polarization</article-title><source>J. Leukocyte Biol.</source><year>2011</year><volume>89</volume><issue>4</issue><fpage>557</fpage><lpage>563</lpage><pub-id pub-id-type="doi">10.1189/jlb.0710409</pub-id><pub-id pub-id-type="pmid">21248152</pub-id><pub-id pub-id-type="pmcid">PMC3058818</pub-id></element-citation></ref><ref id="ref4"><element-citation publication-type="journal" id="cit4"><name name-style="western"><surname>McInnes</surname><given-names>I. B.</given-names></name><name name-style="western"><surname>Schett</surname><given-names>G.</given-names></name><article-title>Pathogenetic insights
from the treatment of rheumatoid
arthritis</article-title><source>Lancet</source><year>2017</year><volume>389</volume><issue>10086</issue><fpage>2328</fpage><lpage>2337</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(17)31472-1</pub-id><pub-id pub-id-type="pmid">28612747</pub-id></element-citation></ref><ref id="ref5"><element-citation publication-type="journal" id="cit5"><name name-style="western"><surname>Yang</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ding</surname><given-names>J.</given-names></name><name name-style="western"><surname>Feng</surname><given-names>X.</given-names></name><name name-style="western"><surname>Chang</surname><given-names>F.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Gao</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Zhuang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>X.</given-names></name><article-title>Scavenger receptor-mediated targeted
treatment of collagen-induced arthritis by dextran sulfate-methotrexate
prodrug</article-title><source>Theranostics</source><year>2017</year><volume>7</volume><issue>1</issue><fpage>97</fpage><pub-id pub-id-type="doi">10.7150/thno.16844</pub-id><pub-id pub-id-type="pmid">28042319</pub-id><pub-id pub-id-type="pmcid">PMC5196888</pub-id></element-citation></ref><ref id="ref6"><element-citation publication-type="journal" id="cit6"><name name-style="western"><surname>Smolen</surname><given-names>J. S.</given-names></name><name name-style="western"><surname>Aletaha</surname><given-names>D.</given-names></name><name name-style="western"><surname>Barton</surname><given-names>A.</given-names></name><name name-style="western"><surname>Burmester</surname><given-names>G.</given-names></name><name name-style="western"><surname>Emery</surname><given-names>P.</given-names></name><name name-style="western"><surname>Firestein</surname><given-names>G.</given-names></name><name name-style="western"><surname>Kavanaugh</surname><given-names>A.</given-names></name><name name-style="western"><surname>McInnes</surname><given-names>I.</given-names></name><name name-style="western"><surname>Solomon</surname><given-names>D.</given-names></name><name name-style="western"><surname>Strand</surname><given-names>V.</given-names></name><etal/><article-title>Rheumatoid
arthritis</article-title><source>Nat. Rev. Dis Primers</source><year>2018</year><volume>4</volume><issue>1</issue><fpage>18001</fpage><pub-id pub-id-type="doi">10.1038/nrdp.2018.1</pub-id><pub-id pub-id-type="pmid">29417936</pub-id></element-citation></ref><ref id="ref7"><element-citation publication-type="journal" id="cit7"><name name-style="western"><surname>Sultana</surname><given-names>F.</given-names></name><name name-style="western"><surname>Neog</surname><given-names>M. K.</given-names></name><name name-style="western"><surname>Rasool</surname><given-names>M.</given-names></name><article-title>Targeted delivery of morin, a dietary
bioflavanol encapsulated mannosylated liposomes to the macrophages
of adjuvant-induced arthritis rats inhibits inflammatory immune response
and osteoclastogenesis</article-title><source>Eur. J. Pharm. Biopharm.</source><year>2017</year><volume>115</volume><fpage>229</fpage><lpage>242</lpage><pub-id pub-id-type="doi">10.1016/j.ejpb.2017.03.009</pub-id><pub-id pub-id-type="pmid">28315446</pub-id></element-citation></ref><ref id="ref8"><element-citation publication-type="journal" id="cit8"><name name-style="western"><surname>Neumann</surname><given-names>E.</given-names></name><name name-style="western"><surname>Lef&#232;vre</surname><given-names>S.</given-names></name><name name-style="western"><surname>Zimmermann</surname><given-names>B.</given-names></name><name name-style="western"><surname>Gay</surname><given-names>S.</given-names></name><name name-style="western"><surname>M&#252;ller-Ladner</surname><given-names>U.</given-names></name><article-title>Rheumatoid
arthritis progression mediated by activated synovial fibroblasts</article-title><source>Trends Mol. Med.</source><year>2010</year><volume>16</volume><issue>10</issue><fpage>458</fpage><lpage>468</lpage><pub-id pub-id-type="doi">10.1016/j.molmed.2010.07.004</pub-id><pub-id pub-id-type="pmid">20739221</pub-id></element-citation></ref><ref id="ref9"><element-citation publication-type="journal" id="cit9"><name name-style="western"><surname>Gibofsky</surname><given-names>A.</given-names></name><article-title>Current therapeutic
agents and treatment paradigms for the management of rheumatoid arthritis</article-title><source>Am. J. Manag. Care</source><year>2014</year><volume>20</volume><issue>7 Suppl</issue><fpage>S136</fpage><lpage>144</lpage><pub-id pub-id-type="pmid">25180622</pub-id></element-citation></ref><ref id="ref10"><element-citation publication-type="journal" id="cit10"><name name-style="western"><surname>Sfikakis</surname><given-names>P. P.</given-names></name><name name-style="western"><surname>Tsokos</surname><given-names>G. C.</given-names></name><article-title>Towards the next generation of anti-TNF
drugs</article-title><source>Clin. Immunol.</source><year>2011</year><volume>141</volume><issue>3</issue><fpage>231</fpage><lpage>235</lpage><pub-id pub-id-type="doi">10.1016/j.clim.2011.09.005</pub-id><pub-id pub-id-type="pmid">22004846</pub-id></element-citation></ref><ref id="ref11"><element-citation publication-type="journal" id="cit11"><name name-style="western"><surname>Lampropoulos</surname><given-names>C. E.</given-names></name><name name-style="western"><surname>Orfanos</surname><given-names>P.</given-names></name><name name-style="western"><surname>Bournia</surname><given-names>V.-K.</given-names></name><name name-style="western"><surname>Karatsourakis</surname><given-names>T.</given-names></name><name name-style="western"><surname>Mavragani</surname><given-names>C.</given-names></name><name name-style="western"><surname>Pikazis</surname><given-names>D.</given-names></name><name name-style="western"><surname>Manoussakis</surname><given-names>M. N.</given-names></name><name name-style="western"><surname>Tzioufas</surname><given-names>A. G.</given-names></name><name name-style="western"><surname>Moutsopoulos</surname><given-names>H. M.</given-names></name><name name-style="western"><surname>Vlachoyiannopoulos</surname><given-names>P. G.</given-names></name><article-title>Adverse
events and infections in patients with rheumatoid arthritis treated
with conventional drugs or biologic agents: A real world study</article-title><source>Clin. Exp. Rheumatol.</source><year>2015</year><volume>33</volume><issue>2</issue><fpage>216</fpage><lpage>224</lpage><pub-id pub-id-type="pmid">25664400</pub-id></element-citation></ref><ref id="ref12"><element-citation publication-type="journal" id="cit12"><name name-style="western"><surname>Meka</surname><given-names>R. R.</given-names></name><name name-style="western"><surname>Venkatesha</surname><given-names>S. H.</given-names></name><name name-style="western"><surname>Moudgil</surname><given-names>K. D.</given-names></name><article-title>Peptide-directed liposomal delivery
improves the therapeutic index of an immunomodulatory cytokine in
controlling autoimmune arthritis</article-title><source>J. Controlled
Release</source><year>2018</year><volume>286</volume><fpage>279</fpage><lpage>288</lpage><pub-id pub-id-type="doi">10.1016/j.jconrel.2018.08.007</pub-id><pub-id pub-id-type="pmcid">PMC6138574</pub-id><pub-id pub-id-type="pmid">30081142</pub-id></element-citation></ref><ref id="ref13"><element-citation publication-type="journal" id="cit13"><name name-style="western"><surname>Ramiro</surname><given-names>S.</given-names></name><name name-style="western"><surname>Sepriano</surname><given-names>A.</given-names></name><name name-style="western"><surname>Chatzidionysiou</surname><given-names>K.</given-names></name><name name-style="western"><surname>Nam</surname><given-names>J. L.</given-names></name><name name-style="western"><surname>Smolen</surname><given-names>J. S.</given-names></name><name name-style="western"><surname>Van Der Heijde</surname><given-names>D.</given-names></name><name name-style="western"><surname>Dougados</surname><given-names>M.</given-names></name><name name-style="western"><surname>Van Vollenhoven</surname><given-names>R.</given-names></name><name name-style="western"><surname>Bijlsma</surname><given-names>J. W.</given-names></name><name name-style="western"><surname>Burmester</surname><given-names>G. R.</given-names></name><etal/><article-title>Safety of synthetic
and biological DMARDs: A systematic literature review informing the
2016 update of the EULAR recommendations for management of rheumatoid
arthritis</article-title><source>Ann. Rheum. Dis.</source><year>2017</year><volume>76</volume><issue>6</issue><fpage>1101</fpage><lpage>1136</lpage><pub-id pub-id-type="doi">10.1136/annrheumdis-2016-210708</pub-id><pub-id pub-id-type="pmid">28298374</pub-id></element-citation></ref><ref id="ref14"><element-citation publication-type="journal" id="cit14"><name name-style="western"><surname>Masarudin</surname><given-names>M. J.</given-names></name><name name-style="western"><surname>Cutts</surname><given-names>S. M.</given-names></name><name name-style="western"><surname>Evison</surname><given-names>B. J.</given-names></name><name name-style="western"><surname>Phillips</surname><given-names>D. R.</given-names></name><name name-style="western"><surname>Pigram</surname><given-names>P. J.</given-names></name><article-title>Factors
determining the stability, size distribution, and cellular accumulation
of small, monodisperse chitosan nanoparticles as candidate vectors
for anticancer drug delivery: Application to the passive encapsulation
of [14C]-doxorubicin</article-title><source>Nanotechnol., Sci. Appl.</source><year>2015</year><fpage>67&#8211;</fpage><lpage>80</lpage><pub-id pub-id-type="doi">10.2147/NSA.S91785</pub-id><pub-id pub-id-type="pmid">26715842</pub-id><pub-id pub-id-type="pmcid">PMC4686320</pub-id></element-citation></ref><ref id="ref15"><element-citation publication-type="journal" id="cit15"><name name-style="western"><surname>Wang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Kang</surname><given-names>Y.-X.</given-names></name><name name-style="western"><surname>Pan</surname><given-names>W.</given-names></name><name name-style="western"><surname>Lei</surname><given-names>W.</given-names></name><name name-style="western"><surname>Feng</surname><given-names>B.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X.-J.</given-names></name><article-title>Enhancement of anti-inflammatory
activity of curcumin
using phosphatidylserine-containing nanoparticles in cultured macrophages</article-title><source>Int. J. Mol. Sci.</source><year>2016</year><volume>17</volume><issue>6</issue><fpage>969</fpage><pub-id pub-id-type="doi">10.3390/ijms17060969</pub-id><pub-id pub-id-type="pmid">27331813</pub-id><pub-id pub-id-type="pmcid">PMC4926501</pub-id></element-citation></ref><ref id="ref16"><element-citation publication-type="journal" id="cit16"><name name-style="western"><surname>Klein</surname><given-names>M. E.</given-names></name><name name-style="western"><surname>Rieckmann</surname><given-names>M.</given-names></name><name name-style="western"><surname>Lucas</surname><given-names>H.</given-names></name><name name-style="western"><surname>Meister</surname><given-names>A.</given-names></name><name name-style="western"><surname>Loppnow</surname><given-names>H.</given-names></name><name name-style="western"><surname>M&#228;der</surname><given-names>K.</given-names></name><article-title>Phosphatidylserine (PS) and phosphatidylglycerol (PG)
enriched mixed micelles (MM): A new nano-drug delivery system with
anti-inflammatory potential?</article-title><source>Eur. J. Pharm.
Sci.</source><year>2020</year><volume>152</volume><fpage>105451</fpage><pub-id pub-id-type="doi">10.1016/j.ejps.2020.105451</pub-id><pub-id pub-id-type="pmid">32621969</pub-id></element-citation></ref><ref id="ref17"><element-citation publication-type="journal" id="cit17"><name name-style="western"><surname>Zhang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Fujii</surname><given-names>S.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Hashioka</surname><given-names>S.</given-names></name><name name-style="western"><surname>Tanaka</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Shiratsuchi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Nakanishi</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Nakanishi</surname><given-names>H.</given-names></name><article-title>Involvement
of COX-1 and up-regulated prostaglandin E synthases in phosphatidylserine
liposome-induced prostaglandin E2 production by microglia</article-title><source>J. Neuroimmunol.</source><year>2006</year><volume>172</volume><issue>1&#8211;2</issue><fpage>112</fpage><lpage>120</lpage><pub-id pub-id-type="doi">10.1016/j.jneuroim.2005.11.008</pub-id><pub-id pub-id-type="pmid">16371234</pub-id></element-citation></ref><ref id="ref18"><element-citation publication-type="journal" id="cit18"><name name-style="western"><surname>Dvoriantchikova</surname><given-names>G.</given-names></name><name name-style="western"><surname>Agudelo</surname><given-names>C.</given-names></name><name name-style="western"><surname>Hernandez</surname><given-names>E.</given-names></name><name name-style="western"><surname>Shestopalov</surname><given-names>V. I.</given-names></name><name name-style="western"><surname>Ivanov</surname><given-names>D.</given-names></name><article-title>Phosphatidylserine-containing liposomes
promote maximal
survival of retinal neurons after ischemic injury</article-title><source>J. Cereb. Blood Flow Metab.</source><year>2009</year><volume>29</volume><issue>11</issue><fpage>1755</fpage><lpage>1759</lpage><pub-id pub-id-type="doi">10.1038/jcbfm.2009.95</pub-id><pub-id pub-id-type="pmid">19675564</pub-id></element-citation></ref><ref id="ref19"><element-citation publication-type="journal" id="cit19"><name name-style="western"><surname>Otsuka</surname><given-names>M.</given-names></name><name name-style="western"><surname>Tsuchiya</surname><given-names>S.</given-names></name><name name-style="western"><surname>Aramaki</surname><given-names>Y.</given-names></name><article-title>Involvement
of ERK, a MAP kinase,
in the production of TGF-&#946; by macrophages treated with liposomes
composed of phosphatidylserine</article-title><source>Biochem. Biophys.
Res. Commun.</source><year>2004</year><volume>324</volume><issue>4</issue><fpage>1400</fpage><lpage>1405</lpage><pub-id pub-id-type="doi">10.1016/j.bbrc.2004.09.198</pub-id><pub-id pub-id-type="pmid">15504369</pub-id></element-citation></ref><ref id="ref20"><element-citation publication-type="journal" id="cit20"><name name-style="western"><surname>Khan</surname><given-names>M. A.</given-names></name><name name-style="western"><surname>Jabeen</surname><given-names>R.</given-names></name><name name-style="western"><surname>Nasti</surname><given-names>T.</given-names></name><name name-style="western"><surname>Mohammad</surname><given-names>O.</given-names></name><article-title>Enhanced anticryptococcal
activity of chloroquine in phosphatidylserine-containing liposomes
in a murine model</article-title><source>J. Antimicrob. Chemother.</source><year>2005</year><volume>55</volume><issue>2</issue><fpage>223</fpage><lpage>228</lpage><pub-id pub-id-type="doi">10.1093/jac/dkh522</pub-id><pub-id pub-id-type="pmid">15590713</pub-id></element-citation></ref><ref id="ref21"><element-citation publication-type="journal" id="cit21"><name name-style="western"><surname>Shi</surname><given-names>D.</given-names></name><name name-style="western"><surname>Fu</surname><given-names>M.</given-names></name><name name-style="western"><surname>Fan</surname><given-names>P.</given-names></name><name name-style="western"><surname>Li</surname><given-names>W.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>X.</given-names></name><name name-style="western"><surname>Li</surname><given-names>C.</given-names></name><name name-style="western"><surname>Qi</surname><given-names>X.</given-names></name><name name-style="western"><surname>Gao</surname><given-names>T.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y.</given-names></name><article-title>Artificial phosphatidylserine liposome
mimics apoptotic cells in inhibiting maturation and immunostimulatory
function of murine myeloid dendritic cells in response to 1-chloro-2,
4-dinitrobenze in vitro</article-title><source>Arch. Dermatol. Res.</source><year>2007</year><volume>299</volume><issue>7</issue><fpage>327</fpage><lpage>336</lpage><pub-id pub-id-type="doi">10.1007/s00403-007-0770-9</pub-id><pub-id pub-id-type="pmid">17643252</pub-id></element-citation></ref><ref id="ref22"><element-citation publication-type="journal" id="cit22"><name name-style="western"><surname>Ichihashi</surname><given-names>T.</given-names></name><name name-style="western"><surname>Satoh</surname><given-names>T.</given-names></name><name name-style="western"><surname>Sugimoto</surname><given-names>C.</given-names></name><name name-style="western"><surname>Kajino</surname><given-names>K.</given-names></name><article-title>Emulsified phosphatidylserine,
simple and effective peptide carrier for induction of potent epitope-specific
T cell responses</article-title><source>PLoS One</source><year>2013</year><volume>8</volume><issue>3</issue><elocation-id>e60068</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0060068</pub-id><pub-id pub-id-type="pmid">23533665</pub-id><pub-id pub-id-type="pmcid">PMC3606214</pub-id></element-citation></ref><ref id="ref23"><element-citation publication-type="journal" id="cit23"><name name-style="western"><surname>Ogawa</surname><given-names>M.</given-names></name><name name-style="western"><surname>Uchino</surname><given-names>R.</given-names></name><name name-style="western"><surname>Kawai</surname><given-names>A.</given-names></name><name name-style="western"><surname>Kosugi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Magata</surname><given-names>Y.</given-names></name><article-title>PEG modification
on 111In-labeled phosphatidyl serine liposomes for imaging of atherosclerotic
plaques</article-title><source>Nucl. Med. Biol.</source><year>2015</year><volume>42</volume><issue>3</issue><fpage>299</fpage><lpage>304</lpage><pub-id pub-id-type="doi">10.1016/j.nucmedbio.2014.12.004</pub-id><pub-id pub-id-type="pmid">25533763</pub-id></element-citation></ref><ref id="ref24"><element-citation publication-type="journal" id="cit24"><name name-style="western"><surname>Kansal</surname><given-names>S.</given-names></name><name name-style="western"><surname>Tandon</surname><given-names>R.</given-names></name><name name-style="western"><surname>Dwivedi</surname><given-names>P.</given-names></name><name name-style="western"><surname>Misra</surname><given-names>P.</given-names></name><name name-style="western"><surname>Verma</surname><given-names>P.</given-names></name><name name-style="western"><surname>Dube</surname><given-names>A.</given-names></name><name name-style="western"><surname>Mishra</surname><given-names>P. R.</given-names></name><article-title>Development
of nanocapsules bearing
doxorubicin for macrophage targeting through the phosphatidylserine
ligand: A system for intervention in visceral leishmaniasis</article-title><source>J. Antimicrob. Chemother.</source><year>2012</year><volume>67</volume><issue>11</issue><fpage>2650</fpage><lpage>2660</lpage><pub-id pub-id-type="doi">10.1093/jac/dks286</pub-id><pub-id pub-id-type="pmid">22872448</pub-id></element-citation></ref><ref id="ref25"><element-citation publication-type="journal" id="cit25"><name name-style="western"><surname>Harel-Adar</surname><given-names>T.</given-names></name><name name-style="western"><surname>Mordechai</surname><given-names>T. B.</given-names></name><name name-style="western"><surname>Amsalem</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Feinberg</surname><given-names>M. S.</given-names></name><name name-style="western"><surname>Leor</surname><given-names>J.</given-names></name><name name-style="western"><surname>Cohen</surname><given-names>S.</given-names></name><article-title>Modulation
of cardiac macrophages by phosphatidylserine-presenting
liposomes improves infarct repair</article-title><source>Proc. Int.
Acad. Sci.</source><year>2011</year><volume>108</volume><issue>5</issue><fpage>1827</fpage><lpage>1832</lpage><pub-id pub-id-type="doi">10.1073/pnas.1015623108</pub-id><pub-id pub-id-type="pmcid">PMC3033268</pub-id><pub-id pub-id-type="pmid">21245355</pub-id></element-citation></ref><ref id="ref26"><element-citation publication-type="journal" id="cit26"><name name-style="western"><surname>Yao</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Kou</surname><given-names>L.</given-names></name><name name-style="western"><surname>Tu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>L.</given-names></name><article-title>MMP-responsive &#8216;smart&#8217;drug
delivery and tumor targeting</article-title><source>Trends Pharmacol.
Sci.</source><year>2018</year><volume>39</volume><issue>8</issue><fpage>766</fpage><lpage>781</lpage><pub-id pub-id-type="doi">10.1016/j.tips.2018.06.003</pub-id><pub-id pub-id-type="pmid">30032745</pub-id></element-citation></ref><ref id="ref27"><element-citation publication-type="journal" id="cit27"><name name-style="western"><surname>Giannelli</surname><given-names>G.</given-names></name><name name-style="western"><surname>Erriquez</surname><given-names>R.</given-names></name><name name-style="western"><surname>Iannone</surname><given-names>F.</given-names></name><name name-style="western"><surname>Marinosci</surname><given-names>F.</given-names></name><name name-style="western"><surname>Lapadula</surname><given-names>G.</given-names></name><name name-style="western"><surname>Antonaci</surname><given-names>S.</given-names></name><article-title>MMP-2, MMP-9, TIMP-1 and TIMP-2 levels
in patients with rheumatoid arthritis and psoriatic arthritis</article-title><source>Clin. Exp. Rheumatol.</source><year>2004</year><volume>22</volume><issue>3</issue><fpage>335</fpage><lpage>338</lpage><pub-id pub-id-type="pmid">15144129</pub-id></element-citation></ref><ref id="ref28"><element-citation publication-type="journal" id="cit28"><name name-style="western"><surname>Itoh</surname><given-names>T.</given-names></name><name name-style="western"><surname>Matsuda</surname><given-names>H.</given-names></name><name name-style="western"><surname>Tanioka</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kuwabara</surname><given-names>K.</given-names></name><name name-style="western"><surname>Itohara</surname><given-names>S.</given-names></name><name name-style="western"><surname>Suzuki</surname><given-names>R.</given-names></name><article-title>The role of matrix metalloproteinase-2 and matrix metalloproteinase-9
in antibody-induced arthritis</article-title><source>J. Immunol.</source><year>2002</year><volume>169</volume><issue>5</issue><fpage>2643</fpage><lpage>2647</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.169.5.2643</pub-id><pub-id pub-id-type="pmid">12193736</pub-id></element-citation></ref><ref id="ref29"><element-citation publication-type="journal" id="cit29"><name name-style="western"><surname>Zhang</surname><given-names>M.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>W.</given-names></name><name name-style="western"><surname>Cai</surname><given-names>C.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Li</surname><given-names>J.</given-names></name><name name-style="western"><surname>Dong</surname><given-names>S.</given-names></name><article-title>Advanced application
of stimuli-responsive drug delivery system for inflammatory arthritis
treatment</article-title><source>Mater. Today Bio</source><year>2022</year><volume>14</volume><fpage>100223</fpage><pub-id pub-id-type="doi">10.1016/j.mtbio.2022.100223</pub-id><pub-id pub-id-type="pmcid">PMC8881671</pub-id><pub-id pub-id-type="pmid">35243298</pub-id></element-citation></ref><ref id="ref30"><element-citation publication-type="journal" id="cit30"><name name-style="western"><surname>Liu</surname><given-names>X.-H.</given-names></name><name name-style="western"><surname>Ding</surname><given-names>J.-Y.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>Z.-H.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>X.-C.</given-names></name><name name-style="western"><surname>Song</surname><given-names>Y.-J.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>X.-L.</given-names></name><name name-style="western"><surname>Ding</surname><given-names>D.-F.</given-names></name><article-title>Recent advances
in enzyme-related
biomaterials for arthritis treatment</article-title><source>Front.
Chem.</source><year>2022</year><volume>10</volume><fpage>988051</fpage><pub-id pub-id-type="doi">10.3389/fchem.2022.988051</pub-id><pub-id pub-id-type="pmid">36051622</pub-id><pub-id pub-id-type="pmcid">PMC9424673</pub-id></element-citation></ref><ref id="ref31"><element-citation publication-type="journal" id="cit31"><name name-style="western"><surname>Mehana</surname><given-names>E.-S. E.</given-names></name><name name-style="western"><surname>Khafaga</surname><given-names>A. F.</given-names></name><name name-style="western"><surname>El-Blehi</surname><given-names>S. S.</given-names></name><article-title>The role
of matrix metalloproteinases
in osteoarthritis pathogenesis: An updated review</article-title><source>Life Sci.</source><year>2019</year><volume>234</volume><fpage>116786</fpage><pub-id pub-id-type="doi">10.1016/j.lfs.2019.116786</pub-id><pub-id pub-id-type="pmid">31445934</pub-id></element-citation></ref><ref id="ref32"><element-citation publication-type="journal" id="cit32"><name name-style="western"><surname>Bian</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Xiang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Ren</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>G.</given-names></name><name name-style="western"><surname>Xiang</surname><given-names>B.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>C.</given-names></name><name name-style="western"><surname>Pei</surname><given-names>S.</given-names></name><name name-style="western"><surname>Guo</surname><given-names>S.</given-names></name><name name-style="western"><surname>Xiao</surname><given-names>L.</given-names></name><article-title>Immunomodulatory roles of metalloproteinases in rheumatoid
arthritis</article-title><source>Front. Pharmacol.</source><year>2023</year><volume>14</volume><fpage>1285455</fpage><pub-id pub-id-type="doi">10.3389/fphar.2023.1285455</pub-id><pub-id pub-id-type="pmid">38035026</pub-id><pub-id pub-id-type="pmcid">PMC10684723</pub-id></element-citation></ref><ref id="ref33"><element-citation publication-type="journal" id="cit33"><name name-style="western"><surname>Zhu</surname><given-names>L.</given-names></name><name name-style="western"><surname>Kate</surname><given-names>P.</given-names></name><name name-style="western"><surname>Torchilin</surname><given-names>V. P.</given-names></name><article-title>Matrix metalloprotease 2-responsive
multifunctional liposomal nanocarrier for enhanced tumor targeting</article-title><source>ACS Nano</source><year>2012</year><volume>6</volume><issue>4</issue><fpage>3491</fpage><lpage>3498</lpage><pub-id pub-id-type="doi">10.1021/nn300524f</pub-id><pub-id pub-id-type="pmid">22409425</pub-id><pub-id pub-id-type="pmcid">PMC3337349</pub-id></element-citation></ref><ref id="ref34"><element-citation publication-type="journal" id="cit34"><name name-style="western"><surname>Liu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Marbach</surname><given-names>S.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>W.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>L.</given-names></name><article-title>Targeting tumor-associated
macrophages by MMP2-sensitive apoptotic
body-mimicking nanoparticles</article-title><source>ACS Appl. Mater.
Interfaces</source><year>2020</year><volume>12</volume><issue>47</issue><fpage>52402</fpage><lpage>52414</lpage><pub-id pub-id-type="doi">10.1021/acsami.0c15983</pub-id><pub-id pub-id-type="pmid">33169982</pub-id><pub-id pub-id-type="pmcid">PMC8229024</pub-id></element-citation></ref><ref id="ref35"><element-citation publication-type="journal" id="cit35"><name name-style="western"><surname>Zhu</surname><given-names>L.</given-names></name><name name-style="western"><surname>Perche</surname><given-names>F.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>T.</given-names></name><name name-style="western"><surname>Torchilin</surname><given-names>V. P.</given-names></name><article-title>Matrix
metalloproteinase 2-sensitive multifunctional polymeric micelles for
tumor-specific co-delivery of siRNA and hydrophobic drugs</article-title><source>Biomaterials</source><year>2014</year><volume>35</volume><issue>13</issue><fpage>4213</fpage><lpage>4222</lpage><pub-id pub-id-type="doi">10.1016/j.biomaterials.2014.01.060</pub-id><pub-id pub-id-type="pmid">24529391</pub-id><pub-id pub-id-type="pmcid">PMC3981970</pub-id></element-citation></ref><ref id="ref36"><element-citation publication-type="journal" id="cit36"><name name-style="western"><surname>Yao</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Kou</surname><given-names>L.</given-names></name><name name-style="western"><surname>Tu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Tang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>L.</given-names></name><article-title>Tumor-targeted
drug delivery and sensitization by MMP2-responsive polymeric micelles</article-title><source>Nanomedicine</source><year>2019</year><volume>19</volume><fpage>71</fpage><lpage>80</lpage><pub-id pub-id-type="doi">10.1016/j.nano.2019.03.012</pub-id><pub-id pub-id-type="pmid">31004812</pub-id><pub-id pub-id-type="pmcid">PMC6599579</pub-id></element-citation></ref><ref id="ref37"><element-citation publication-type="journal" id="cit37"><name name-style="western"><surname>Yu</surname><given-names>C.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Guo</surname><given-names>C.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Su</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Guo</surname><given-names>H.</given-names></name><name name-style="western"><surname>Hou</surname><given-names>X.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>F.</given-names></name><name name-style="western"><surname>Fan</surname><given-names>H.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>Y.</given-names></name><article-title>Dextran sulfate-based
MMP-2 enzyme-sensitive SR-A receptor targeting nanomicelles for the
treatment of rheumatoid arthritis</article-title><source>Drug Delivery</source><year>2022</year><volume>29</volume><issue>1</issue><fpage>454</fpage><lpage>465</lpage><pub-id pub-id-type="doi">10.1080/10717544.2022.2032482</pub-id><pub-id pub-id-type="pmid">35119317</pub-id><pub-id pub-id-type="pmcid">PMC8855847</pub-id></element-citation></ref><ref id="ref38"><element-citation publication-type="journal" id="cit38"><name name-style="western"><surname>Li</surname><given-names>N.</given-names></name><name name-style="western"><surname>Qiao</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Xue</surname><given-names>L.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>S.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>N.</given-names></name><article-title>Targeted and
MMP-2/9 responsive peptides for the treatment of rheumatoid arthritis</article-title><source>Int. J. Pharm.</source><year>2019</year><volume>569</volume><fpage>118625</fpage><pub-id pub-id-type="doi">10.1016/j.ijpharm.2019.118625</pub-id><pub-id pub-id-type="pmid">31425817</pub-id></element-citation></ref><ref id="ref39"><element-citation publication-type="journal" id="cit39"><name name-style="western"><surname>Dai</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Yao</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>L.</given-names></name><article-title>MMP2-sensitive PEG&#8211;lipid copolymers: A new type
of tumor-targeted P-glycoprotein inhibitor</article-title><source>ACS Appl. Mater. Interfaces</source><year>2016</year><volume>8</volume><issue>20</issue><fpage>12661</fpage><lpage>12673</lpage><pub-id pub-id-type="doi">10.1021/acsami.6b03064</pub-id><pub-id pub-id-type="pmid">27145021</pub-id></element-citation></ref><ref id="ref40"><element-citation publication-type="journal" id="cit40"><name name-style="western"><surname>Yao</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Choi</surname><given-names>J. H.</given-names></name><name name-style="western"><surname>Dai</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>D.</given-names></name><name name-style="western"><surname>Tang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>L.</given-names></name><article-title>Improving
tumor specificity and anticancer
activity of dasatinib by dual-targeted polymeric micelles</article-title><source>ACS Appl. Mater. Interfaces</source><year>2017</year><volume>9</volume><issue>42</issue><fpage>36642</fpage><lpage>36654</lpage><pub-id pub-id-type="doi">10.1021/acsami.7b12233</pub-id><pub-id pub-id-type="pmid">28960955</pub-id></element-citation></ref><ref id="ref41"><element-citation publication-type="journal" id="cit41"><name name-style="western"><surname>Rodr&#237;guez-Varela</surname><given-names>C.</given-names></name><name name-style="western"><surname>Labarta</surname><given-names>E.</given-names></name><article-title>Does coenzyme
Q10 supplementation improve human oocyte
quality?</article-title><source>Int. J. Mol. Sci.</source><year>2021</year><volume>22</volume><issue>17</issue><fpage>9541</fpage><pub-id pub-id-type="doi">10.3390/ijms22179541</pub-id><pub-id pub-id-type="pmid">34502447</pub-id><pub-id pub-id-type="pmcid">PMC8431086</pub-id></element-citation></ref><ref id="ref42"><element-citation publication-type="journal" id="cit42"><name name-style="western"><surname>Rabanal-Ruiz</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Llanos-Gonz&#225;lez</surname><given-names>E.</given-names></name><name name-style="western"><surname>Alcain</surname><given-names>F. J.</given-names></name><article-title>The use of coenzyme
Q10 in cardiovascular diseases</article-title><source>Antioxidants</source><year>2021</year><volume>10</volume><issue>5</issue><fpage>755</fpage><pub-id pub-id-type="doi">10.3390/antiox10050755</pub-id><pub-id pub-id-type="pmid">34068578</pub-id><pub-id pub-id-type="pmcid">PMC8151454</pub-id></element-citation></ref><ref id="ref43"><element-citation publication-type="journal" id="cit43"><name name-style="western"><surname>Mirmalek</surname><given-names>S. A.</given-names></name><name name-style="western"><surname>Gholamrezaei Boushehrinejad</surname><given-names>A.</given-names></name><name name-style="western"><surname>Yavari</surname><given-names>H.</given-names></name><name name-style="western"><surname>Kardeh</surname><given-names>B.</given-names></name><name name-style="western"><surname>Parsa</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Salimi-Tabatabaee</surname><given-names>S.
A.</given-names></name><name name-style="western"><surname>Yadollah-Damavandi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Parsa</surname><given-names>T.</given-names></name><name name-style="western"><surname>Shahverdi</surname><given-names>E.</given-names></name><name name-style="western"><surname>Jangholi</surname><given-names>E.</given-names></name><article-title>Antioxidant and anti-inflammatory
effects of coenzyme Q10 on L-arginine-induced acute pancreatitis in
rat</article-title><source>Oxid. Med. Cell. Longev.</source><year>2016</year><volume>2016</volume><issue>1</issue><fpage>5818479</fpage><pub-id pub-id-type="doi">10.1155/2016/5818479</pub-id><pub-id pub-id-type="pmid">27190575</pub-id><pub-id pub-id-type="pmcid">PMC4844882</pub-id></element-citation></ref><ref id="ref44"><element-citation publication-type="journal" id="cit44"><name name-style="western"><surname>Sifuentes-Franco</surname><given-names>S.</given-names></name><name name-style="western"><surname>S&#225;nchez-Mac&#237;as</surname><given-names>D. C.</given-names></name><name name-style="western"><surname>Carrillo-Ibarra</surname><given-names>S.</given-names></name><name name-style="western"><surname>Rivera-Vald&#233;s</surname><given-names>J. J.</given-names></name><name name-style="western"><surname>Zu&#241;iga</surname><given-names>L. Y.</given-names></name><name name-style="western"><surname>S&#225;nchez-L&#243;pez</surname><given-names>V. A.</given-names></name><article-title>Antioxidant and anti-inflammatory
effects of coenzyme Q10 supplementation on infectious diseases</article-title><source>Healthcare</source><year>2022</year><volume>10</volume><fpage>487</fpage><pub-id pub-id-type="doi">10.3390/healthcare10030487</pub-id><pub-id pub-id-type="pmid">35326965</pub-id><pub-id pub-id-type="pmcid">PMC8953254</pub-id></element-citation></ref><ref id="ref45"><element-citation publication-type="journal" id="cit45"><name name-style="western"><surname>Diaz</surname><given-names>D. A.</given-names></name><name name-style="western"><surname>Colgan</surname><given-names>S. T.</given-names></name><name name-style="western"><surname>Langer</surname><given-names>C. S.</given-names></name><name name-style="western"><surname>Bandi</surname><given-names>N.</given-names></name><name name-style="western"><surname>Likar</surname><given-names>M. D.</given-names></name><name name-style="western"><surname>Van Alstine</surname><given-names>L.</given-names></name><article-title>Erratum to:
Dissolution Similarity Requirements: How
Similar or Dissimilar Are the Global Regulatory Expectations?</article-title><source>AAPS J.</source><year>2016</year><volume>18</volume><issue>3</issue><fpage>792</fpage><pub-id pub-id-type="doi">10.1208/s12248-015-9835-4</pub-id><pub-id pub-id-type="pmid">26538124</pub-id><pub-id pub-id-type="pmcid">PMC5256595</pub-id></element-citation></ref><ref id="ref46"><element-citation publication-type="journal" id="cit46"><name name-style="western"><surname>Zhai</surname><given-names>S.</given-names></name><name name-style="western"><surname>Mathew</surname><given-names>T.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>Y.</given-names></name><article-title>Comparison of drug
dissolution profiles:
A proposal based on tolerance limits</article-title><source>Stat.
Med.</source><year>2016</year><volume>35</volume><issue>29</issue><fpage>5464</fpage><lpage>5476</lpage><pub-id pub-id-type="doi">10.1002/sim.7072</pub-id><pub-id pub-id-type="pmid">27501158</pub-id></element-citation></ref><ref id="ref200"><element-citation publication-type="journal" id="cit200"><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name><article-title>DDSolver:
an add-in program for modeling and comparison of drug dissolution
profiles</article-title><source>AAPS J</source><year>2010</year><volume>12</volume><fpage>263</fpage><lpage>271</lpage><pub-id pub-id-type="pmid">20373062</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1208/s12248-010-9185-1</pub-id><pub-id pub-id-type="pmcid">PMC2895453</pub-id></element-citation></ref><ref id="ref47"><element-citation publication-type="journal" id="cit47"><name name-style="western"><surname>Boddeda</surname><given-names>B.</given-names></name><name name-style="western"><surname>Kumari</surname><given-names>P. V.</given-names></name><name name-style="western"><surname>Chowdary</surname><given-names>K. P. R.</given-names></name><article-title>Formulation and evaluation of glipizide
sustained release tablets</article-title><source>Int. J. Pharm.</source><year>2012</year><volume>3</volume><issue>1</issue><fpage>44</fpage><lpage>48</lpage></element-citation></ref><ref id="ref48"><element-citation publication-type="journal" id="cit48"><name name-style="western"><surname>Kunde</surname><given-names>S. D.</given-names></name><name name-style="western"><surname>Sh</surname><given-names>B.</given-names></name><name name-style="western"><surname>Godbole</surname><given-names>A.</given-names></name><name name-style="western"><surname>Gajre</surname><given-names>P.</given-names></name><article-title>Biopharmaceutical classification
system: A brief account</article-title><source>Int. J. Sci. Res. Methodol.</source><year>2015</year><volume>1</volume><issue>1</issue><fpage>20</fpage><lpage>46</lpage></element-citation></ref><ref id="ref49"><element-citation publication-type="journal" id="cit49"><name name-style="western"><surname>Quinzii</surname><given-names>C.
M.</given-names></name><name name-style="western"><surname>Lopez</surname><given-names>L. C.</given-names></name><name name-style="western"><surname>Von-Moltke</surname><given-names>J.</given-names></name><name name-style="western"><surname>Naini</surname><given-names>A.</given-names></name><name name-style="western"><surname>Krishna</surname><given-names>S.</given-names></name><name name-style="western"><surname>Schuelke</surname><given-names>M.</given-names></name><name name-style="western"><surname>Salviati</surname><given-names>L.</given-names></name><name name-style="western"><surname>Navas</surname><given-names>P.</given-names></name><name name-style="western"><surname>DiMauro</surname><given-names>S.</given-names></name><name name-style="western"><surname>Hirano</surname><given-names>M.</given-names></name><article-title>Respiratory
chain dysfunction and oxidative stress
correlate with severity of primary CoQ10 deficiency</article-title><source>FASEB J.</source><year>2008</year><volume>22</volume><issue>6</issue><fpage>1874</fpage><lpage>1885</lpage><pub-id pub-id-type="doi">10.1096/fj.07-100149</pub-id><pub-id pub-id-type="pmid">18230681</pub-id><pub-id pub-id-type="pmcid">PMC2731482</pub-id></element-citation></ref><ref id="ref50"><element-citation publication-type="journal" id="cit50"><name name-style="western"><surname>Bentinger</surname><given-names>M.</given-names></name><name name-style="western"><surname>Brismar</surname><given-names>K.</given-names></name><name name-style="western"><surname>Dallner</surname><given-names>G.</given-names></name><article-title>The antioxidant
role of coenzyme
Q</article-title><source>Mitochondrion</source><year>2007</year><volume>7</volume><fpage>S41</fpage><lpage>S50</lpage><pub-id pub-id-type="doi">10.1016/j.mito.2007.02.006</pub-id><pub-id pub-id-type="pmid">17482888</pub-id></element-citation></ref><ref id="ref51"><element-citation publication-type="journal" id="cit51"><name name-style="western"><surname>Mantle</surname><given-names>D.</given-names></name><name name-style="western"><surname>Heaton</surname><given-names>R. A.</given-names></name><name name-style="western"><surname>Hargreaves</surname><given-names>I. P.</given-names></name><article-title>Coenzyme
Q10 and immune function:
An overview</article-title><source>Antioxidants</source><year>2021</year><volume>10</volume><issue>5</issue><fpage>759</fpage><pub-id pub-id-type="doi">10.3390/antiox10050759</pub-id><pub-id pub-id-type="pmid">34064686</pub-id><pub-id pub-id-type="pmcid">PMC8150987</pub-id></element-citation></ref><ref id="ref52"><element-citation publication-type="journal" id="cit52"><name name-style="western"><surname>Liu</surname><given-names>L.</given-names></name><name name-style="western"><surname>Mao</surname><given-names>K.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>W.</given-names></name><name name-style="western"><surname>Pan</surname><given-names>H.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>F.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>M.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>H.</given-names></name><article-title>Kolliphor&#174;HS 15
micelles for the delivery of coenzyme Q10: Preparation,
characterization, and stability</article-title><source>AAPS PharmSciTech</source><year>2016</year><volume>17</volume><fpage>757</fpage><lpage>766</lpage><pub-id pub-id-type="doi">10.1208/s12249-015-0399-5</pub-id><pub-id pub-id-type="pmid">26340950</pub-id></element-citation></ref><ref id="ref53"><element-citation publication-type="journal" id="cit53"><name name-style="western"><surname>Zhu</surname><given-names>L.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>T.</given-names></name><name name-style="western"><surname>Perche</surname><given-names>F.</given-names></name><name name-style="western"><surname>Taigind</surname><given-names>A.</given-names></name><name name-style="western"><surname>Torchilin</surname><given-names>V. P.</given-names></name><article-title>Enhanced
anticancer activity of nanopreparation containing an MMP2-sensitive
PEG-drug conjugate and cell-penetrating moiety</article-title><source>Proc. Int. Acad. Sci.</source><year>2013</year><volume>110</volume><issue>42</issue><fpage>17047</fpage><lpage>17052</lpage><pub-id pub-id-type="doi">10.1073/pnas.1304987110</pub-id><pub-id pub-id-type="pmcid">PMC3801051</pub-id><pub-id pub-id-type="pmid">24062440</pub-id></element-citation></ref><ref id="ref54"><element-citation publication-type="journal" id="cit54"><name name-style="western"><surname>Tu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>L.</given-names></name><article-title>Enhancing cancer targeting
and anticancer activity by a stimulus-sensitive
multifunctional polymer-drug conjugate</article-title><source>J. Controlled
Release</source><year>2015</year><volume>212</volume><fpage>94</fpage><lpage>102</lpage><pub-id pub-id-type="doi">10.1016/j.jconrel.2015.06.024</pub-id><pub-id pub-id-type="pmid">26113423</pub-id></element-citation></ref><ref id="ref55"><element-citation publication-type="journal" id="cit55"><name name-style="western"><surname>Torchilin</surname><given-names>V. P.</given-names></name><article-title>Micellar
nanocarriers: Pharmaceutical perspectives</article-title><source>Pharm.
Res.</source><year>2006</year><volume>24</volume><fpage>1</fpage><lpage>16</lpage><pub-id pub-id-type="doi">10.1007/s11095-006-9132-0</pub-id><pub-id pub-id-type="pmid">17109211</pub-id></element-citation></ref><ref id="ref56"><element-citation publication-type="journal" id="cit56"><name name-style="western"><surname>Yao</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Dai</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Hoon Choi</surname><given-names>J.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>D.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>L.</given-names></name><article-title>Building stable MMP2-responsive
multifunctional polymeric micelles by an all-in-one polymer&#8211;lipid
conjugate for tumor-targeted intracellular drug delivery</article-title><source>ACS Appl. Mater. Interfaces</source><year>2017</year><volume>9</volume><issue>38</issue><fpage>32520</fpage><lpage>32533</lpage><pub-id pub-id-type="doi">10.1021/acsami.7b09511</pub-id><pub-id pub-id-type="pmid">28870072</pub-id></element-citation></ref><ref id="ref57"><element-citation publication-type="journal" id="cit57"><name name-style="western"><surname>Suk</surname><given-names>J. S.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>N.</given-names></name><name name-style="western"><surname>Hanes</surname><given-names>J.</given-names></name><name name-style="western"><surname>Ensign</surname><given-names>L. M.</given-names></name><article-title>PEGylation as a
strategy for improving nanoparticle-based drug and gene delivery</article-title><source>Adv. Drug Delivery Rev.</source><year>2016</year><volume>99</volume><fpage>28</fpage><lpage>51</lpage><pub-id pub-id-type="doi">10.1016/j.addr.2015.09.012</pub-id><pub-id pub-id-type="pmcid">PMC4798869</pub-id><pub-id pub-id-type="pmid">26456916</pub-id></element-citation></ref><ref id="ref58"><element-citation publication-type="journal" id="cit58"><name name-style="western"><surname>Song</surname><given-names>H.</given-names></name><name name-style="western"><surname>Yin</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Peng</surname><given-names>J.</given-names></name><name name-style="western"><surname>Du</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Bao</surname><given-names>W.</given-names></name><article-title>Preparation Characteristics,
and Controlled Release Efficiency of the Novel PCL-PEG/EM Rod Micelles</article-title><source>J. Nanomater.</source><year>2021</year><volume>2021</volume><fpage>1</fpage><lpage>10</lpage><pub-id pub-id-type="doi">10.1155/2021/8132868</pub-id></element-citation></ref><ref id="ref59"><element-citation publication-type="journal" id="cit59"><name name-style="western"><surname>Perumal</surname><given-names>S.</given-names></name><name name-style="western"><surname>Atchudan</surname><given-names>R.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>W.</given-names></name><article-title>A review of polymeric micelles and
their applications</article-title><source>Polymers</source><year>2022</year><volume>14</volume><issue>12</issue><fpage>2510</fpage><pub-id pub-id-type="doi">10.3390/polym14122510</pub-id><pub-id pub-id-type="pmid">35746086</pub-id><pub-id pub-id-type="pmcid">PMC9230755</pub-id></element-citation></ref><ref id="ref60"><element-citation publication-type="journal" id="cit60"><name name-style="western"><surname>McMahon</surname><given-names>D. J.</given-names></name><name name-style="western"><surname>Brown</surname><given-names>R. J.</given-names></name><article-title>Composition, structure,
and integrity of casein micelles:
A review</article-title><source>J. Dairy Sci.</source><year>1984</year><volume>67</volume><issue>3</issue><fpage>499</fpage><lpage>512</lpage><pub-id pub-id-type="doi">10.3168/jds.S0022-0302(84)81332-6</pub-id></element-citation></ref><ref id="ref61"><element-citation publication-type="journal" id="cit61"><name name-style="western"><surname>Malekhosseini</surname><given-names>S.</given-names></name><name name-style="western"><surname>Rezaie</surname><given-names>A.</given-names></name><name name-style="western"><surname>Khaledian</surname><given-names>S.</given-names></name><name name-style="western"><surname>Abdoli</surname><given-names>M.</given-names></name><name name-style="western"><surname>Zangeneh</surname><given-names>M. M.</given-names></name><name name-style="western"><surname>Hosseini</surname><given-names>A.</given-names></name><name name-style="western"><surname>Behbood</surname><given-names>L.</given-names></name><article-title>Fabrication
and characterization
of hydrocortisone loaded Dextran-Poly Lactic-co-Glycolic acid micelle</article-title><source>Heliyon</source><year>2020</year><volume>6</volume><issue>5</issue><elocation-id>e03975</elocation-id><pub-id pub-id-type="doi">10.1016/j.heliyon.2020.e03975</pub-id><pub-id pub-id-type="pmid">32455174</pub-id><pub-id pub-id-type="pmcid">PMC7235624</pub-id></element-citation></ref><ref id="ref62"><element-citation publication-type="journal" id="cit62"><name name-style="western"><surname>Nayebsadrian</surname><given-names>M.</given-names></name><name name-style="western"><surname>Varshosaz</surname><given-names>J.</given-names></name><name name-style="western"><surname>Hassanzadeh</surname><given-names>F.</given-names></name><name name-style="western"><surname>Sadeghi</surname><given-names>H.</given-names></name><name name-style="western"><surname>Banitalebi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Rostami</surname><given-names>M.</given-names></name><article-title>Screening the most
effective variables on physical
properties of folate-targeted dextran/retinoic acid micelles by taguchi
design</article-title><source>J. Nanomater.</source><year>2012</year><volume>2012</volume><issue>1</issue><fpage>860691</fpage><pub-id pub-id-type="doi">10.1155/2012/860691</pub-id></element-citation></ref><ref id="ref63"><element-citation publication-type="journal" id="cit63"><name name-style="western"><surname>Grzelczak</surname><given-names>M.</given-names></name><name name-style="western"><surname>Vermant</surname><given-names>J.</given-names></name><name name-style="western"><surname>Furst</surname><given-names>E. M.</given-names></name><name name-style="western"><surname>Liz-Marzan</surname><given-names>L. M.</given-names></name><article-title>Directed
self-assembly of nanoparticles</article-title><source>ACS Nano</source><year>2010</year><volume>4</volume><issue>7</issue><fpage>3591</fpage><lpage>3605</lpage><pub-id pub-id-type="doi">10.1021/nn100869j</pub-id><pub-id pub-id-type="pmid">20568710</pub-id></element-citation></ref><ref id="ref64"><element-citation publication-type="journal" id="cit64"><name name-style="western"><surname>Sanchez-Iglesias</surname><given-names>A.</given-names></name><name name-style="western"><surname>Grzelczak</surname><given-names>M.</given-names></name><name name-style="western"><surname>Altantzis</surname><given-names>T.</given-names></name><name name-style="western"><surname>Goris</surname><given-names>B.</given-names></name><name name-style="western"><surname>Perez-Juste</surname><given-names>J.</given-names></name><name name-style="western"><surname>Bals</surname><given-names>S.</given-names></name><name name-style="western"><surname>Van Tendeloo</surname><given-names>G.</given-names></name><name name-style="western"><surname>Donaldson</surname><given-names>S. H.</given-names><suffix>Jr.</suffix></name><name name-style="western"><surname>Chmelka</surname><given-names>B. F.</given-names></name><name name-style="western"><surname>Israelachvili</surname><given-names>J. N.</given-names></name><etal/><article-title>Hydrophobic interactions modulate self-assembly of nanoparticles</article-title><source>ACS Nano</source><year>2012</year><volume>6</volume><issue>12</issue><fpage>11059</fpage><lpage>11065</lpage><pub-id pub-id-type="doi">10.1021/nn3047605</pub-id><pub-id pub-id-type="pmid">23186074</pub-id></element-citation></ref><ref id="ref65"><element-citation publication-type="journal" id="cit65"><name name-style="western"><surname>Lukyanov</surname><given-names>A. N.</given-names></name><name name-style="western"><surname>Gao</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Mazzola</surname><given-names>L.</given-names></name><name name-style="western"><surname>Torchilin</surname><given-names>V. P.</given-names></name><article-title>Polyethylene glycol-diacyllipid micelles
demonstrate increased accumulation in subcutaneous tumors in mice</article-title><source>Pharm. Res.</source><year>2002</year><volume>19</volume><fpage>1424</fpage><lpage>1429</lpage><pub-id pub-id-type="doi">10.1023/A:1020488012264</pub-id><pub-id pub-id-type="pmid">12425458</pub-id></element-citation></ref><ref id="ref66"><element-citation publication-type="journal" id="cit66"><name name-style="western"><surname>Lukyanov</surname><given-names>A. N.</given-names></name><name name-style="western"><surname>Torchilin</surname><given-names>V. P.</given-names></name><article-title>Micelles from lipid derivatives of water-soluble polymers
as delivery systems for poorly soluble drugs</article-title><source>Adv. Drug Delivery Rev.</source><year>2004</year><volume>56</volume><issue>9</issue><fpage>1273</fpage><lpage>1289</lpage><pub-id pub-id-type="doi">10.1016/j.addr.2003.12.004</pub-id><pub-id pub-id-type="pmid">15109769</pub-id></element-citation></ref><ref id="ref67"><element-citation publication-type="journal" id="cit67"><name name-style="western"><surname>Cehakova</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ivanisova</surname><given-names>D.</given-names></name><name name-style="western"><surname>Strecanska</surname><given-names>M.</given-names></name><name name-style="western"><surname>Plava</surname><given-names>J.</given-names></name><name name-style="western"><surname>Varchulova
Novakova</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Nicodemou</surname><given-names>A.</given-names></name><name name-style="western"><surname>Harsanyi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Culenova</surname><given-names>M.</given-names></name><name name-style="western"><surname>Bernatova</surname><given-names>S.</given-names></name><name name-style="western"><surname>Danisovic</surname><given-names>L.</given-names></name><article-title>Rheumatoid synovial fluid and acidic
extracellular pH modulate the immunomodulatory activity of urine-derived
stem cells</article-title><source>Int. J. Mol. Sci.</source><year>2023</year><volume>24</volume><issue>21</issue><fpage>15856</fpage><pub-id pub-id-type="doi">10.3390/ijms242115856</pub-id><pub-id pub-id-type="pmid">37958839</pub-id><pub-id pub-id-type="pmcid">PMC10648750</pub-id></element-citation></ref><ref id="ref68"><element-citation publication-type="journal" id="cit68"><name name-style="western"><surname>Wang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Cao</surname><given-names>W.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>C.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>M.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>J.</given-names></name><article-title>Development
of pH-sensitive dextran-based methotrexate nanodrug for rheumatoid
arthritis therapy through inhibition of JAK-STAT pathways</article-title><source>Int. J. Pharm.</source><year>2022</year><volume>622</volume><fpage>121874</fpage><pub-id pub-id-type="doi">10.1016/j.ijpharm.2022.121874</pub-id><pub-id pub-id-type="pmid">35636630</pub-id></element-citation></ref><ref id="ref69"><element-citation publication-type="journal" id="cit69"><name name-style="western"><surname>Li</surname><given-names>J. X.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>M. J.</given-names></name><name name-style="western"><surname>Shi</surname><given-names>J. F.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>S. P.</given-names></name><name name-style="western"><surname>Zhong</surname><given-names>X. M.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>Y. H.</given-names></name><name name-style="western"><surname>Qu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Le Gao</surname><given-names>H.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>J. M.</given-names></name><article-title>pH-sensitive
nano-polyelectrolyte complexes with arthritic macrophage-targeting
delivery of triptolide</article-title><source>Int. J. Pharm.</source><year>2023</year><volume>632</volume><fpage>122572</fpage><pub-id pub-id-type="doi">10.1016/j.ijpharm.2022.122572</pub-id><pub-id pub-id-type="pmid">36592894</pub-id></element-citation></ref><ref id="ref70"><element-citation publication-type="journal" id="cit70"><name name-style="western"><surname>Jin</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Ge</surname><given-names>X.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>S.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Deng</surname><given-names>A.</given-names></name><name name-style="western"><surname>Li</surname><given-names>J.</given-names></name><name name-style="western"><surname>Gu</surname><given-names>Z.</given-names></name><article-title>A pH-responsive DNA
tetrahedron/methotrexate drug delivery
system used for rheumatoid arthritis treatment</article-title><source>J. Funct. Biomater.</source><year>2023</year><volume>14</volume><issue>11</issue><fpage>541</fpage><pub-id pub-id-type="doi">10.3390/jfb14110541</pub-id><pub-id pub-id-type="pmid">37998110</pub-id><pub-id pub-id-type="pmcid">PMC10672632</pub-id></element-citation></ref><ref id="ref71"><element-citation publication-type="journal" id="cit71"><name name-style="western"><surname>Lombardi</surname><given-names>A. F.</given-names></name><name name-style="western"><surname>Ma</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Jang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Jerban</surname><given-names>S.</given-names></name><name name-style="western"><surname>Tang</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Searleman</surname><given-names>A. C.</given-names></name><name name-style="western"><surname>Meyer</surname><given-names>R. S.</given-names></name><name name-style="western"><surname>Du</surname><given-names>J.</given-names></name><name name-style="western"><surname>Chang</surname><given-names>E. Y.</given-names></name><article-title>AcidoCEST-UTE MRI
Reveals an Acidic Microenvironment in Knee Osteoarthritis</article-title><source>Int. J. Mol. Sci.</source><year>2022</year><volume>23</volume><issue>8</issue><fpage>4466</fpage><pub-id pub-id-type="doi">10.3390/ijms23084466</pub-id><pub-id pub-id-type="pmid">35457284</pub-id><pub-id pub-id-type="pmcid">PMC9027981</pub-id></element-citation></ref><ref id="ref72"><element-citation publication-type="journal" id="cit72"><name name-style="western"><surname>Ren</surname><given-names>H.</given-names></name><name name-style="western"><surname>He</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Liang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>M.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Hong</surname><given-names>C.</given-names></name><name name-style="western"><surname>Qin</surname><given-names>J.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J.</given-names></name><article-title>Role of Liposome
Size, Surface Charge, and PEGylation on Rheumatoid Arthritis Targeting
Therapy</article-title><source>ACS Appl. Mater. Interfaces</source><year>2019</year><volume>11</volume><issue>22</issue><fpage>20304</fpage><lpage>20315</lpage><pub-id pub-id-type="doi">10.1021/acsami.8b22693</pub-id><pub-id pub-id-type="pmid">31056910</pub-id></element-citation></ref><ref id="ref73"><element-citation publication-type="journal" id="cit73"><name name-style="western"><surname>Cho</surname><given-names>H.-Y.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>C. K.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>Y.-B.</given-names></name><article-title>Preparation and evaluation of PEGylated
and folate-PEGylated liposomes containing paclitaxel for lymphatic
delivery</article-title><source>J. Nanomater.</source><year>2015</year><volume>2015</volume><issue>1</issue><fpage>471283</fpage><pub-id pub-id-type="doi">10.1155/2015/471283</pub-id></element-citation></ref><ref id="ref74"><element-citation publication-type="journal" id="cit74"><name name-style="western"><surname>Xiao</surname><given-names>K.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Luo</surname><given-names>J.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>J. S.</given-names></name><name name-style="western"><surname>Xiao</surname><given-names>W.</given-names></name><name name-style="western"><surname>Gonik</surname><given-names>A. M.</given-names></name><name name-style="western"><surname>Agarwal</surname><given-names>R. G.</given-names></name><name name-style="western"><surname>Lam</surname><given-names>K. S.</given-names></name><article-title>The effect of surface charge on in
vivo biodistribution of PEG-oligocholic acid based micellar nanoparticles</article-title><source>Biomaterials</source><year>2011</year><volume>32</volume><issue>13</issue><fpage>3435</fpage><lpage>3446</lpage><pub-id pub-id-type="doi">10.1016/j.biomaterials.2011.01.021</pub-id><pub-id pub-id-type="pmid">21295849</pub-id><pub-id pub-id-type="pmcid">PMC3055170</pub-id></element-citation></ref><ref id="ref75"><element-citation publication-type="journal" id="cit75"><name name-style="western"><surname>Lee</surname><given-names>B.-J.</given-names></name><name name-style="western"><surname>Tseng</surname><given-names>Y.-F.</given-names></name><name name-style="western"><surname>Yen</surname><given-names>C.-H.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>P.-T.</given-names></name><article-title>Effects of coenzyme
Q10 supplementation (300 mg/day) on antioxidation and anti-inflammation
in coronary artery disease patients during statins therapy: A randomized,
placebo-controlled trial</article-title><source>Nutr. J.</source><year>2013</year><volume>12</volume><issue>1</issue><fpage>142</fpage><pub-id pub-id-type="doi">10.1186/1475-2891-12-142</pub-id><pub-id pub-id-type="pmid">24192015</pub-id><pub-id pub-id-type="pmcid">PMC4176102</pub-id></element-citation></ref><ref id="ref76"><element-citation publication-type="journal" id="cit76"><name name-style="western"><surname>Shults</surname><given-names>C. W.</given-names></name><name name-style="western"><surname>Beal</surname><given-names>M. F.</given-names></name><name name-style="western"><surname>Song</surname><given-names>D.</given-names></name><name name-style="western"><surname>Fontaine</surname><given-names>D.</given-names></name><article-title>Pilot trial
of high
dosages of coenzyme Q10 in patients with Parkinson&#8217;s disease</article-title><source>Exp. Neurol.</source><year>2004</year><volume>188</volume><issue>2</issue><fpage>491</fpage><lpage>494</lpage><pub-id pub-id-type="doi">10.1016/j.expneurol.2004.05.003</pub-id><pub-id pub-id-type="pmid">15246848</pub-id></element-citation></ref><ref id="ref77"><element-citation publication-type="journal" id="cit77"><name name-style="western"><surname>Sguizzato</surname><given-names>M.</given-names></name><name name-style="western"><surname>Mariani</surname><given-names>P.</given-names></name><name name-style="western"><surname>Spinozzi</surname><given-names>F.</given-names></name><name name-style="western"><surname>Benedusi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Cervellati</surname><given-names>F.</given-names></name><name name-style="western"><surname>Cortesi</surname><given-names>R.</given-names></name><name name-style="western"><surname>Drechsler</surname><given-names>M.</given-names></name><name name-style="western"><surname>Prieux</surname><given-names>R.</given-names></name><name name-style="western"><surname>Valacchi</surname><given-names>G.</given-names></name><name name-style="western"><surname>Esposito</surname><given-names>E.</given-names></name><article-title>Ethosomes for coenzyme
Q10 cutaneous administration:
From design to 3D skin tissue evaluation</article-title><source>Antioxidants</source><year>2020</year><volume>9</volume><issue>6</issue><fpage>485</fpage><pub-id pub-id-type="doi">10.3390/antiox9060485</pub-id><pub-id pub-id-type="pmid">32503293</pub-id><pub-id pub-id-type="pmcid">PMC7346166</pub-id></element-citation></ref><ref id="ref78"><element-citation publication-type="journal" id="cit78"><name name-style="western"><surname>Yang</surname><given-names>H.-L.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>M.-W.</given-names></name><name name-style="western"><surname>Korivi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>J.-J.</given-names></name><name name-style="western"><surname>Liao</surname><given-names>C.-H.</given-names></name><name name-style="western"><surname>Chang</surname><given-names>C.-T.</given-names></name><name name-style="western"><surname>Liao</surname><given-names>J.-W.</given-names></name><name name-style="western"><surname>Hseu</surname><given-names>Y.-C.</given-names></name><article-title>Coenzyme Q0 regulates
NF&#954;B/AP-1 activation and enhances Nrf2 stabilization in attenuation
of LPS-induced inflammation and redox imbalance: Evidence from in
vitro and in vivo studies</article-title><source>Biochim. Biophys.
Acta, Gene Regul. Mech.</source><year>2016</year><volume>1859</volume><issue>2</issue><fpage>246</fpage><lpage>261</lpage><pub-id pub-id-type="doi">10.1016/j.bbagrm.2015.11.001</pub-id><pub-id pub-id-type="pmid">26548719</pub-id></element-citation></ref><ref id="ref79"><element-citation publication-type="journal" id="cit79"><name name-style="western"><surname>Hidaka</surname><given-names>T.</given-names></name><name name-style="western"><surname>Fujii</surname><given-names>K.</given-names></name><name name-style="western"><surname>Funahashi</surname><given-names>I.</given-names></name><name name-style="western"><surname>Fukutomi</surname><given-names>N.</given-names></name><name name-style="western"><surname>Hosoe</surname><given-names>K.</given-names></name><article-title>Safety assessment
of coenzyme Q10 (CoQ10)</article-title><source>BioFactors</source><year>2008</year><volume>32</volume><issue>1&#8211;4</issue><fpage>199</fpage><lpage>208</lpage><pub-id pub-id-type="doi">10.1002/biof.5520320124</pub-id><pub-id pub-id-type="pmid">19096117</pub-id></element-citation></ref><ref id="ref80"><element-citation publication-type="journal" id="cit80"><name name-style="western"><surname>Hassanzadeh</surname><given-names>S.</given-names></name><name name-style="western"><surname>Jameie</surname><given-names>S. B.</given-names></name><name name-style="western"><surname>Soleimani</surname><given-names>M.</given-names></name><name name-style="western"><surname>Farhadi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kerdari</surname><given-names>M.</given-names></name><name name-style="western"><surname>Danaei</surname><given-names>N.</given-names></name><article-title>Coenzyme Q10 influences on the levels of TNF-&#945;
and IL-10 and the ratio of Bax/Bcl2 in a menopausal rat model following
lumbar spinal cord injury</article-title><source>J. Mol. Neurosci.</source><year>2018</year><volume>65</volume><fpage>255</fpage><lpage>264</lpage><pub-id pub-id-type="doi">10.1007/s12031-018-1090-6</pub-id><pub-id pub-id-type="pmid">29948851</pub-id></element-citation></ref><ref id="ref81"><element-citation publication-type="journal" id="cit81"><name name-style="western"><surname>Jhun</surname><given-names>J.</given-names></name><name name-style="western"><surname>Moon</surname><given-names>J.</given-names></name><name name-style="western"><surname>Ryu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Shin</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>S.</given-names></name><name name-style="western"><surname>Cho</surname><given-names>K.-H.</given-names></name><name name-style="western"><surname>Kang</surname><given-names>T.</given-names></name><name name-style="western"><surname>Cho</surname><given-names>M.-L.</given-names></name><name name-style="western"><surname>Park</surname><given-names>S.-H.</given-names></name><article-title>Liposome/gold
hybrid nanoparticle encoded with CoQ10 (LGNP-CoQ10) suppressed rheumatoid
arthritis via STAT3/Th17 targeting</article-title><source>PLoS One</source><year>2020</year><volume>15</volume><issue>11</issue><elocation-id>e0241080</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0241080</pub-id><pub-id pub-id-type="pmid">33156836</pub-id><pub-id pub-id-type="pmcid">PMC7647073</pub-id></element-citation></ref><ref id="ref82"><element-citation publication-type="journal" id="cit82"><name name-style="western"><surname>Abdollahzad</surname><given-names>H.</given-names></name><name name-style="western"><surname>Aghdashi</surname><given-names>M. A.</given-names></name><name name-style="western"><surname>Jafarabadi</surname><given-names>M. A.</given-names></name><name name-style="western"><surname>Alipour</surname><given-names>B.</given-names></name><article-title>Effects of coenzyme
Q10 supplementation on inflammatory cytokines (TNF-&#945;, IL-6)
and oxidative stress in rheumatoid arthritis patients: A randomized
controlled trial</article-title><source>Arch. Med. Res.</source><year>2015</year><volume>46</volume><issue>7</issue><fpage>527</fpage><lpage>533</lpage><pub-id pub-id-type="doi">10.1016/j.arcmed.2015.08.006</pub-id><pub-id pub-id-type="pmid">26342738</pub-id></element-citation></ref><ref id="ref83"><element-citation publication-type="journal" id="cit83"><name name-style="western"><surname>Wang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>J. S.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>D.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>L.</given-names></name><article-title>Exploration of Zinc
Oxide Nanoparticles as a Multitarget and Multifunctional Anticancer
Nanomedicine</article-title><source>ACS Appl. Mater. Interfaces</source><year>2017</year><volume>9</volume><issue>46</issue><fpage>39971</fpage><lpage>39984</lpage><pub-id pub-id-type="doi">10.1021/acsami.7b11219</pub-id><pub-id pub-id-type="pmid">29076344</pub-id></element-citation></ref><ref id="ref84"><element-citation publication-type="journal" id="cit84"><name name-style="western"><surname>Rosales</surname><given-names>C.</given-names></name><name name-style="western"><surname>Uribe-Querol</surname><given-names>E.</given-names></name><article-title>Phagocytosis: A fundamental process in immunity</article-title><source>Biomed. Res. Int.</source><year>2017</year><volume>2017</volume><issue>1</issue><fpage>9042851</fpage><pub-id pub-id-type="doi">10.1155/2017/9042851</pub-id><pub-id pub-id-type="pmid">28691037</pub-id><pub-id pub-id-type="pmcid">PMC5485277</pub-id></element-citation></ref><ref id="ref85"><element-citation publication-type="journal" id="cit85"><name name-style="western"><surname>Bartok</surname><given-names>B.</given-names></name><name name-style="western"><surname>Firestein</surname><given-names>G. S.</given-names></name><article-title>Fibroblast-like synoviocytes: Key effector cells in
rheumatoid arthritis</article-title><source>Immunol. Rev.</source><year>2010</year><volume>233</volume><issue>1</issue><fpage>233</fpage><lpage>255</lpage><pub-id pub-id-type="doi">10.1111/j.0105-2896.2009.00859.x</pub-id><pub-id pub-id-type="pmid">20193003</pub-id><pub-id pub-id-type="pmcid">PMC2913689</pub-id></element-citation></ref><ref id="ref86"><element-citation publication-type="journal" id="cit86"><name name-style="western"><surname>Ding</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>W.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>R.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>M.</given-names></name><name name-style="western"><surname>Li</surname><given-names>M.</given-names></name><name name-style="western"><surname>Cai</surname><given-names>J.</given-names></name><name name-style="western"><surname>Rose</surname><given-names>P.</given-names></name><name name-style="western"><surname>Mao</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>Y. Z.</given-names></name><article-title>Signaling pathways
in rheumatoid arthritis: Implications for targeted therapy</article-title><source>Signal Transduct. Target. Ther.</source><year>2023</year><volume>8</volume><issue>1</issue><fpage>68</fpage><pub-id pub-id-type="doi">10.1038/s41392-023-01331-9</pub-id><pub-id pub-id-type="pmid">36797236</pub-id><pub-id pub-id-type="pmcid">PMC9935929</pub-id></element-citation></ref><ref id="ref87"><element-citation publication-type="journal" id="cit87"><name name-style="western"><surname>Zhou</surname><given-names>M.</given-names></name><name name-style="western"><surname>Qin</surname><given-names>S.</given-names></name><name name-style="western"><surname>Chu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>F.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>L.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>Y.</given-names></name><article-title>Immunolocalization
of MMP-2 and MMP-9 in human rheumatoid synovium</article-title><source>Int. J. Clin. Exp. Pathol.</source><year>2014</year><volume>7</volume><issue>6</issue><fpage>3048</fpage><lpage>56</lpage><pub-id pub-id-type="pmid">25031723</pub-id><pub-id pub-id-type="pmcid">PMC4097284</pub-id></element-citation></ref><ref id="ref88"><element-citation publication-type="journal" id="cit88"><name name-style="western"><surname>Burrage</surname><given-names>P. S.</given-names></name><name name-style="western"><surname>Mix</surname><given-names>K. S.</given-names></name><name name-style="western"><surname>Brinckerhoff</surname><given-names>C. E.</given-names></name><article-title>Matrix metalloproteinases: Role in
arthritis</article-title><source>Front Biosci.</source><year>2006</year><volume>11</volume><issue>1</issue><fpage>529</fpage><lpage>543</lpage><pub-id pub-id-type="doi">10.2741/1817</pub-id><pub-id pub-id-type="pmid">16146751</pub-id></element-citation></ref><ref id="ref89"><element-citation publication-type="journal" id="cit89"><name name-style="western"><surname>Wang</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Qin</surname><given-names>X.</given-names></name><name name-style="western"><surname>Fang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>X.</given-names></name><article-title>Nanomedicines for the treatment of
rheumatoid arthritis: State of art and potential therapeutic strategies</article-title><source>Acta Pharm. Sin. B</source><year>2021</year><volume>11</volume><issue>5</issue><fpage>1158</fpage><lpage>1174</lpage><pub-id pub-id-type="doi">10.1016/j.apsb.2021.03.013</pub-id><pub-id pub-id-type="pmid">34094826</pub-id><pub-id pub-id-type="pmcid">PMC8144894</pub-id></element-citation></ref><ref id="ref90"><element-citation publication-type="journal" id="cit90"><name name-style="western"><surname>Guo</surname><given-names>R.-B.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>X.-Y.</given-names></name><name name-style="western"><surname>Yan</surname><given-names>D.-K.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>Y.-J.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.-J.</given-names></name><name name-style="western"><surname>Geng</surname><given-names>H.-X.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>Y.-N.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Kong</surname><given-names>L.</given-names></name><name name-style="western"><surname>Li</surname><given-names>X.-T.</given-names></name><article-title>Folate-modified triptolide liposomes
target activated macrophages
for safe rheumatoid arthritis therapy</article-title><source>Biomater.
Sci.</source><year>2022</year><volume>10</volume><issue>2</issue><fpage>499</fpage><lpage>513</lpage><pub-id pub-id-type="doi">10.1039/D1BM01520F</pub-id><pub-id pub-id-type="pmid">34904598</pub-id></element-citation></ref><ref id="ref91"><element-citation publication-type="journal" id="cit91"><name name-style="western"><surname>Zheng</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wei</surname><given-names>K.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>P.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>J.</given-names></name><name name-style="western"><surname>Shan</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Shi</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>F.</given-names></name><name name-style="western"><surname>Chang</surname><given-names>C.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>M.</given-names></name><etal/><article-title>Macrophage polarization in rheumatoid arthritis: Signaling pathways,
metabolic reprogramming, and crosstalk with synovial fibroblasts</article-title><source>Front. Immunol.</source><year>2024</year><volume>15</volume><fpage>1394108</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2024.1394108</pub-id><pub-id pub-id-type="pmid">38799455</pub-id><pub-id pub-id-type="pmcid">PMC11116671</pub-id></element-citation></ref></ref-list></back></article>
        
    </metadata>
</record>
    </GetRecord>

</OAI-PMH>